A Deeper Dive into Advanced and Future Directions in Treating Patients with Acute Myeloid Leukemia

Sandra Kurtin, PhDc, ANP-C, AOCN®
The University of Arizona Cancer Center

Gabrielle Zecha, PA-C
The University of Washington
Learning Objectives

• Describe the latest WHO disease definitions for AML
• Recall the mechanism of action for novel therapies for treatment of AML
• Summarize the clinical relevance of molecular mutations in AML, including FLT3 and IDH2
• Identify germline mutations in patients with a predisposition for AML
Financial Disclosure

- Ms. Kurtin served as a consultant for Jazz, Celgene, Novartis, Genentech, and Incyte.
- Ms. Zecha has no disclosures to report.

This activity is supported by unrestricted educational grants from Astellas Pharma Global Development, Inc. and Jazz Pharmaceuticals.
Audience Response Questions

Please indicate the clinical role that best represents you:

1. Physician
2. PA
3. Nurse practitioner
4. Clinical nurse specialist
5. Nurse
6. Pharmacist
7. Other
Please indicate the practice setting that best represents your practice:

1. Academic medical center, teaching hospital, or comprehensive cancer center
2. Community hospital or community cancer center
3. Private/group practice
4. Government or VA
5. Managed care, insurance, employer, or other payer
6. Pharmaceutical/biotech/device industry
7. Other
Please indicate your clinical specialty:

1. Medical oncology
2. Hematology/oncology
3. Radiation oncology
4. Internal medicine
5. Gynecologic oncology
6. Genetics/genetic counseling
7. Other
Please indicate your years in practice:

1. < 1 year
2. 1–5 years
3. 6–10 years
4. 11–15 years
5. 16–20 years
6. > 20 years
Question #1

Your 74-year-old patient was just started on enasidenib, an oral mIDH2 inhibitor that promotes myeloid differentiation of leukemic blasts. He complains of shortness of breath and fever; on auscultation, you hear crackles and note he has pitting ankle edema and a temperature of 101.7 degrees. You suspect:

1. He has neutropenia and has contracted pneumonia
2. He has IDH inhibitor–associated differentiation syndrome
3. He has a cardiac history and needs a cardiac consult
4. He has retinoic acid syndrome
5. I’m unsure
Your patient has been diagnosed with relapsed AML after initial treatment. Testing with next-generation sequencing has revealed an IDH2 mutation. What is your choice of treatment?

1. Enasidenib
2. Gemtuzumab
3. Midostaurin
4. Quizartinib
5. I’m unsure
Question #3

Which recently approved anti-CD33 monoclonal antibody has a history that underscores the importance of examining alternative dosing, scheduling, and administration of therapies for patients with acute myeloid leukemia (AML), especially in those who may be most vulnerable to the side effects of treatment?

1. Ofatumumab
2. Rituximab
3. Gemtuzumab ozogamicin
4. Ipilimumab
5. I’m unsure
You have a 67-year-old male patient with FLT3-positive AML who received a standard dose of cytarabine and daunorubicin 1 year ago and is now presenting with a relapse. The phase I/II CHRYSLALIS study results were the first demonstration of molecular response to a FLT3 inhibitor in AML. Your patient may be a good candidate for the ongoing registrational ADMIRAL trial for patients with relapsed/refractory FLT3+ AML. Which therapy is being studied in this trial?

1. Enasidenib
2. Quizartinib
3. Midostaurin
4. Gilteritinib
5. I’m unsure
Patients receiving high-dose chemotherapy for the treatment of AML are at an increased risk of neutropenic fever and sepsis. So timely initiation of antibiotic treatment is critical. A 2006 study of 2,154 patients showed a survival rate of 80%, if antibiotics are administered within how long after documented hypotension?

1. 24 hours
2. 3 days
3. 1 hour
4. 12 hours
5. I’m unsure
The History of AML

- Acute leukemias represent a group of clonal neoplastic disorders of hematopoietic progenitor cells
- They were first described in 1845 by Dr. Rudolph Virchow

Gilliland, G., & Reffel, G. Molecular Biology of Acute Leukemias. In Cancer: Principles and Practice of Oncology, Vincent T. DeVita, Jr., MD; Samuel Hellman, MD; and Steven A. Rosenberg, MD, PhD, eds. Lippincott Williams & Wilkins, 2005 Edition; 2077-2088
## AML: New Cases and Deaths

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>21,380</td>
<td>10,590</td>
<td>68</td>
<td>26.9%</td>
</tr>
</tbody>
</table>

- Median Age at Diagnosis = 68
- Median Age at Death = 78

Risk Factors

- Unknown in > 80% of patients
- Age, male gender
- Mutagenic/genotoxic stress
- Antineoplastic therapies
  - Therapeutic alkylators (e.g., cyclophosphamide)
  - Topoisomerase II inhibitors (e.g., mitoxantrone, etoposide)
  - HSCT (autologous or allogeneic)
  - Prior treatment for ALL, especially as a child
- Environmental/occupational
  - Ionizing radiation
  - Chemical exposures
    - Benzenes, insecticides
    - Hydrocarbons
  - Tobacco, especially after age 60
  - Antecedent hematological malignancies - MDS
  - Rare, inherited congenital abnormalities
    - Fanconi anemia, familial MDS, Down syndrome

ALL = acute lymphoblastic leukemia; HSCT = hematopoietic stem cell transplantation; MDS = myelodysplastic syndrome.
Presenting Signs and Symptoms

- Generally abrupt onset
- Fever
- Shortness of breath
- Easy bruising, bleeding, petechiae
- Progressive fatigue, malaise
- Weight loss or loss of appetite
- Skin nodules or gingival hyperplasia in selected subtypes
## Diagnostic Evaluation: History and Physical

<table>
<thead>
<tr>
<th>Evaluation</th>
<th>Clinical Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Document onset of suspicious symptoms, acute episodes of illness transfusion history, historical labs</td>
<td>Assist in establishing time for onset of disease&lt;br&gt;Thorough family history needed to identify potential myeloid neoplasms with germ-line predisposition</td>
</tr>
<tr>
<td>Review of medication profile</td>
<td>Identification of any drug induced cytopenias potential drug interactions</td>
</tr>
<tr>
<td>Comorbid conditions</td>
<td>Effective management of comorbid conditions may play a critical role in selecting potential therapies&lt;br&gt;History of CHF, history of herpes simplex, transfusion history, previous malignancies and treatment of particular interest in AML</td>
</tr>
<tr>
<td>Physical Exam</td>
<td>Establish a baseline and identification of any abnormal findings, which may require immediate intervention</td>
</tr>
</tbody>
</table>

AML = acute myelogenous leukemia; CHF = congestive heart failure.

## Diagnostic Evaluation: Peripheral Blood

<table>
<thead>
<tr>
<th>Diagnostic Study</th>
<th>Clinical Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDH, uric acid, PO4, Ca++, K+</td>
<td>Tumor lysis screen, elevated LDH is a poor prognostic indicator</td>
</tr>
<tr>
<td>LDH, haptoglobin, reticulocyte count, coombs</td>
<td>Evaluate for possible underlying hemolysis</td>
</tr>
<tr>
<td>Coagulation profile</td>
<td>Presence of DIC—particularly important in APL</td>
</tr>
<tr>
<td>Fibrinogen, PT, PTT, D-dimer</td>
<td></td>
</tr>
<tr>
<td>HLA typing</td>
<td>For possible BMT</td>
</tr>
<tr>
<td>Lumbar puncture</td>
<td>CNS involvement</td>
</tr>
<tr>
<td>Hepatitis A, B, C; HIV-1 testing</td>
<td>Increased risk of treatment-related morbidity</td>
</tr>
<tr>
<td>Serum pregnancy testing</td>
<td>Women of childbearing age</td>
</tr>
</tbody>
</table>

APL = acute promyelocytic leukemia; BMT = bone marrow transplant; CNS = central nervous system; DIC = disseminated intravascular coagulation; HLA = human leukocyte antigen; LDH = lactate dehydrogenase; PT = prothrombin time; PTT = partial thromboplastin time.

## Diagnostic Evaluation: Bone Marrow

<table>
<thead>
<tr>
<th>Diagnostic Study</th>
<th>Clinical Significance</th>
</tr>
</thead>
</table>
| Aspirate (should include spicules and be cellular enough to assess at least 500 cells) | • Evaluation of morphological abnormalities of hematopoietic precursors to allow WHO classification  
• Used for flow cytometry (immunophenotyping), FISH, cytogenetics, and molecular testing  
• A marrow or blood blast count of ≥ 20% is required, except for AML with t(15;17), t(8;21), inv(16), or t(16;16); myeloblasts, monoblasts, and megakaryoblasts are included in the blast count  
• In AML with monocytic or myelomonocytic differentiation, monoblasts and promonocytes, but not abnormal monocytes, are counted as blast equivalents |
| Biopsy (should be adequate size for evaluation [2 cm-2.5 cm]) | • Evaluate cellularity, topography, exclusion of other bone marrow disorders  
• Two cores may be obtained in patients that are dry taps  
• Peripheral blood may assist in the these cases in patients with elevated WBC and circulating blasts |

FISH = fluorescent in situ hybridization; WBC = white blood cell; WHO = World Health Organization.

Molecular/Genetic Testing

- Cytogenetics
  - Metaphase: 20 metaphases, > 2 metaphases considered non-random
  - FISH
- Screening for gene mutations
  - NPM1, CEBPA, RUNX1, FLT3, TP53, ASXL1, IDH2
- Screening for gene rearrangements
  - PML-RARA, CBFB-MYH11, RUNX1-RUNX1T1, BCR-ABL1, other fusion genes

# Diagnostic Evaluation: Radiology

<table>
<thead>
<tr>
<th>Diagnostic Study</th>
<th>Clinical Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chest x-ray</td>
<td>Baseline evaluation, presence of infection</td>
</tr>
<tr>
<td>12 lead EKG</td>
<td>Baseline cardiac function</td>
</tr>
<tr>
<td>MUGA scan, echocardiogram</td>
<td>Baseline cardiac function</td>
</tr>
<tr>
<td>CT of the brain without contrast</td>
<td>If CNS disease or hemorrhage is suspected</td>
</tr>
<tr>
<td>MRI of the brain</td>
<td>If leukemic meningitis is suspected</td>
</tr>
<tr>
<td>PET/CT</td>
<td>If clinical suspicion for extramedullary disease</td>
</tr>
<tr>
<td>Central line placement</td>
<td>Required for treatment and supportive care</td>
</tr>
</tbody>
</table>

CT = computed tomography; EKG = electrocardiogram; MRI = magnetic resonance imaging; MUGA = multigated acquisition; PET = positron emission tomography.

Cutaneous Manifestations

- Gingival Hyperplasia
- Leukemia Cutis

Images courtesy of Sandra Kurtin, University of Arizona Cancer Center.
2016 Revision of the WHO Classification of Myeloid Neoplasms

New classification system is focused on underlying mutations/molecular profile

- Myeloid neoplasms with germ-line predisposition without a preexisting disorder or organ dysfunction
  - AML with germ-line CEBPA mutation
  - Myeloid neoplasms with germ-line DDX41 mutation

- Myeloid neoplasms with germ-line predisposition and preexisting platelet disorders
  - Myeloid neoplasms with germ-line RUNX1 mutation
  - Myeloid neoplasms with germ-line ANKRD26 mutation
  - Myeloid neoplasms with germ-line ETV6 mutation

- Myeloid neoplasms with germ-line predisposition and other organ dysfunction
  - Myeloid neoplasms with germ-line GATA2 mutation
  - Myeloid neoplasms associated with bone marrow failure syndromes
  - Juvenile myelomonocytic leukemia associated with neurofibromatosis, Noonan syndrome, or Noonan syndrome-like disorders
  - Myeloid neoplasms associated with Noonan syndrome
  - Myeloid neoplasms associated with Down syndrome

2016 Revision of the WHO Classification: AML and Related Neoplasms

AML is a complex, dynamic disease, characterized by multiple somatically acquired driver mutations, coexisting competing clones, and disease evolution over time.

- **AML with recurrent genetic abnormalities**
  - AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1
  - AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11
  - APL with PML-RARA
  - AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A
  - AML with t(6;9)(p23;q34.1);DEK-NUP214
  - AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM
  - AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1
  - Provisional entity: AML with BCR-ABL1
  - AML with mutated NPM1
  - AML with biallelic mutations of CEBPA
  - Provisional entity: AML with mutated RUNX1

- **AML with myelodysplasia-related changes**

- **Therapy-related myeloid neoplasms**

- **AML, not otherwise specified**
  - AML with minimal differentiation
  - AML without maturation
  - AML with maturation
  - Acute myelomonocytic leukemia
  - Acute monoblastic/monocytic leukemia
  - Pure erythroid leukemia
  - Acute megakaryoblastic leukemia
  - Acute basophilic leukemia
  - Acute panmyelosis with myelofibrosis

Molecular Classes of AML and Concurrent Gene Mutations in Adult Patients up to age ~65 Years

Risk Stratification: Factors Associated with Poor Risk

- Not considered candidates for intensive therapy
  - Physiologic age
  - Poor performance status
  - Complex or poorly controlled comorbidities
- AML-related genetic factors

Risk Stratification: Age

### 2017 ELN Risk Stratification by Genetics: AML

<table>
<thead>
<tr>
<th>Risk Category</th>
<th>Genetic Abnormality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Favorable</td>
<td>t(8;21)(q22;q22.1); RUNX1-RUNX1T1</td>
</tr>
<tr>
<td></td>
<td>inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11</td>
</tr>
<tr>
<td></td>
<td>Mutated NPM1 without FLT3-ITD or with FLT3-ITD&lt;sup&gt;Low&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Biallelic mutated CEBPA</td>
</tr>
<tr>
<td>Intermediate</td>
<td>Mutated NPM1 and FLT3-ITD&lt;sup&gt;High&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Wild-type NPM1 without FLT3-ITD or with FLT3-ITD&lt;sup&gt;Low&lt;/sup&gt; (without adverse-risk genetic lesions)</td>
</tr>
<tr>
<td></td>
<td>t(9;11)(p21.3;q23.3); MLLT3-KMT2A</td>
</tr>
<tr>
<td></td>
<td>Cytogenetic abnormalities not classified as favorable or adverse</td>
</tr>
</tbody>
</table>

ELN = European Leukemia Network; ITD = internal tandem duplication.
# 2017 ELN Risk Stratification by Genetics: AML

<table>
<thead>
<tr>
<th>Risk Category</th>
<th>Genetic Abnormality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse</td>
<td>t(6;9)(p23;q34.1); <em>DEK-NUP214</em></td>
</tr>
<tr>
<td></td>
<td>t(v;11q23.3); <em>KMT2A</em> rearranged</td>
</tr>
<tr>
<td></td>
<td>t(9;22)(q34.1;q11.2); <em>BCR-ABL1</em></td>
</tr>
<tr>
<td></td>
<td>inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); <em>GATA2, MECOM (EVI1)</em></td>
</tr>
<tr>
<td></td>
<td>-5 or del(5q); -7; -17/ abnormal (17p)</td>
</tr>
<tr>
<td></td>
<td>Complex karyotype; monosomally abnormal</td>
</tr>
<tr>
<td></td>
<td><strong>Wild-type <em>NPM1</em> and <em>FLT3-ITD</em>High</strong></td>
</tr>
<tr>
<td>Mutated</td>
<td><em>RUNX1</em></td>
</tr>
<tr>
<td>Mutated</td>
<td><em>ASXL1</em></td>
</tr>
<tr>
<td>Mutated</td>
<td><em>TP53</em></td>
</tr>
</tbody>
</table>

Predominant Driver Mutations in AML


1,540 patients with AML
Probability of Survival Estimates: *TP53, NPM1, FLT3*

Therapy-Related Myeloid Neoplasms

- Time to onset varies by treatment
- Alkylating agents/radiotherapy: latency period of 5-10 years
- Topoisomerase II inhibitors: latency period 2-3 years
Cytogenetic and Molecular Attributers in tAML, tMDS, and sAML

Frequency % of cytogenetic aberrations (n = 3,654)

Frequency % of molecular aberrations (n = 102)

sAML = secondary AML; tAML = therapy-related AML; tMDS = therapy-related MDS.
Indications to Treat and Goals of Therapy

- Treatment is initiated at the time of diagnosis
  - Delay in induction therapy for 7 days does not affect outcomes in older patients—allows for complete characterization of disease
  - The majority of adults with AML who achieve a CR eventually relapse and few are cured
  - Determining suitability for transplant is a critical part of treatment decision making
  - Aggressive therapy as bridge to transplant vs. palliative approach

- Induction therapy
  - Suppression of the malignant clone with induced hypoplasia, resolution of extramedullary sites of disease

- Consolidation and maintenance therapy
  - Achieving a durable molecular remission with eradication of minimal residual disease
  - Sustain MRD-negative status

- Allogeneic bone marrow transplantation remains the only potentially curative therapy for AML

- Aggressive supportive care required regardless of therapeutic intent (transfusions, antibiotics)

CR = complete remission.

**Eligibility for Intensive Therapy: HCT-CI**

<table>
<thead>
<tr>
<th>Comorbidity</th>
<th>Definition in HCT-CI</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arrhythmia</td>
<td>Atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias</td>
<td>1</td>
</tr>
<tr>
<td>Cardiac</td>
<td>Coronary artery disease, congestive heart failure, myocardial infarction, or EF ≤ 50%</td>
<td>1</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Crohn’s disease or ulcerative colitis</td>
<td>1</td>
</tr>
<tr>
<td>Diabetes</td>
<td>Requiring insulin or oral hypoglycemic</td>
<td>1</td>
</tr>
<tr>
<td>Cerebrovascular disease</td>
<td>TIA or CVA</td>
<td>1</td>
</tr>
<tr>
<td>Psychiatric</td>
<td>Depression or anxiety requiring psychiatric consult or treatment</td>
<td>1</td>
</tr>
<tr>
<td>Hepatic, mild</td>
<td>Chronic hepatitis, bilirubin &gt; ULN to 1.5 ULN, or AST/ALT &gt; ULN to 2.5 ULN</td>
<td>1</td>
</tr>
<tr>
<td>Obesity</td>
<td>Patients with a BMI &gt; 35 kg/m²</td>
<td>1</td>
</tr>
<tr>
<td>Infection</td>
<td>Requiring continuation of antimicrobial treatment after day 0</td>
<td>1</td>
</tr>
</tbody>
</table>

# Eligibility for Intensive Therapy: HCT-CI

<table>
<thead>
<tr>
<th>Comorbidity</th>
<th>Definition in HCT-CI</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rheumatologic</td>
<td>SLE, RA, polymyositis, mixed CTD, or PMR</td>
<td>2</td>
</tr>
<tr>
<td>Peptic ulcer</td>
<td>Requiring treatment</td>
<td>2</td>
</tr>
<tr>
<td>Moderate/severe renal</td>
<td>Serum creatinine &gt; 2 mg/dL, on dialysis, or prior renal transplantation</td>
<td>2</td>
</tr>
<tr>
<td>Moderate pulmonary</td>
<td>DLco and/or FEV1 66–88% of dyspnea on slight activity</td>
<td>2</td>
</tr>
<tr>
<td>Prior solid tumor</td>
<td>Treated at any time point in the patient’s past history, excluding non-melanoma skin cancer</td>
<td>3</td>
</tr>
<tr>
<td>Heart valve disease</td>
<td>Except mitral valve disease</td>
<td>3</td>
</tr>
<tr>
<td>Severe pulmonary</td>
<td>DLco and/or FEV1 65% or dyspnea at rest or requiring oxygen</td>
<td>3</td>
</tr>
<tr>
<td>Moderate/severe hepatic</td>
<td>Liver cirrhosis, bilirubin &gt; 1.5 ULN, or AST/ALT &gt; 2.5 ULN</td>
<td>3</td>
</tr>
</tbody>
</table>

## Eligibility for Intensive Therapy: HCT-CI AML Composite Score

<table>
<thead>
<tr>
<th>Additional Factors</th>
<th>Definition in HCT-CI</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-49</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>50-59</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>60-69</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>≥ 70</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td><strong>Cytogenetic/molecular risks</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Favorable</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Intermediate</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Adverse</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

HCT-CI Score >3 Associated with Inferior Outcomes

Cumulative Incidence of Nonrelapse Mortality

Overall Survival (%)

n = 1,180

HCT-CI + Chronological Age: Composite Score

Age ≥ 40 years was assigned a score of 1 to be added to the HCT-CI scores

### Eligibility for Intensive Therapy: HCT-CI AML Composite Score

<table>
<thead>
<tr>
<th>Additional Factors</th>
<th>Definition in HCT-CI</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>0-49</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>50-59</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>60-69</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>&gt; 70</td>
<td>2</td>
</tr>
<tr>
<td>Cytogenetic/ molecular risks</td>
<td>Favorable</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Intermediate</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Adverse</td>
<td>2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Additional Factors</th>
<th>Definition in HCT-CI</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albumin</td>
<td>&lt; 4.0-3.5</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>&lt; 3.5-3.0</td>
<td>1</td>
</tr>
<tr>
<td>Platelet count x10^3 µL</td>
<td>&lt; 100-50</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>&lt; 50-20</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>&lt; 20</td>
<td>1</td>
</tr>
<tr>
<td>LDH level, U/L</td>
<td>&gt; 200-500</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>&gt; 500-1000</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>&gt; 1000</td>
<td>2</td>
</tr>
</tbody>
</table>
The AML Composite Model

Treatment Approach for Newly Diagnosed AML

*If not yet received hypomethylating agent.
**If HSCT eligible
Cyto = cytogenetics.

Induction and Consolidation in AML

Induction therapy (all ages) (“7+3”)
3 days of an IV anthracycline:
daunorubicin at least 60 mg/m²; idarubicin
12 mg/m²; or mitoxantrone 12 mg/m², and 7 days of
continuous infusion cytarabine (100-200 mg/m²)

Day 14 bone marrow

Residual disease
Reinduction when clinically feasible

Hypoplasia
Continue supportive care until marrow recovery

Recovery marrow Day 28+

Residual disease
Clinical trial or salvage therapy

No evidence of disease
Proceed to consolidation

IV = intravenously.
Treatment Approach for Newly Diagnosed AML

*If no prior exposure to hypomethylating agents.
BM = bone marrow. LD Ara-C = low-dose cytarabine.
Induction Therapy with 7+3: 44 Years Later

- In 1973, Yates and colleagues reported results from an AML regimen of 7 days of cytarabine and 3 days of daunorubicin, aka “7+3”
- 40 years later, 7+3 induction therapy continues to benefit patients with AML
  - CR rate in younger patients: 60% to 75%
  - CR rate in patients older than age 60 years: 35% to 50%
- Relapse is inevitable for the majority of patients
- Current trials are focused on adding agents to the 7+3 over the course of treatment, changing the pharmacokinetics of daunorubicin + cytarabine, or finding new targets/pathways that are actionable

Low-Intensity Treatment

- Azacitidine: 75 mg/m$^2$, SC, d1-7, every 4 weeks, until progression
- Decitabine: 20 mg/m$^2$, IV, d1-5, every 4 weeks, until progression
- Low-dose cytarabine (20 mg every 12 hours, SC, d1-10, every 4 weeks; until progression); not recommended in patients with adverse-risk genetics
- Best supportive care Including hydroxyurea; for patients who cannot tolerate any antileukemic therapy, or who do not wish any therapy

SC = subcutaneously.
Novel Agents for the Treatment of AML
# Selected Novel Agents Used to Treat AML

<table>
<thead>
<tr>
<th>Agent</th>
<th>MOA</th>
<th>Suggested Population</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPX-351</td>
<td>Liposomal 7+3 in 5:1 molar ratio</td>
<td>sAML fit for induction chemotherapy</td>
<td>Phase II: OS benefit in sAML; phase III: OS, EFS benefit; FDA approval August 2017</td>
</tr>
<tr>
<td>Midostaurin</td>
<td>Inhibitor of FLT3, c-KIT, PDGFRB, VEGFR-2, and protein kinase C</td>
<td>Newly diagnosed, FLT3+ in combination with standard 7+3 induction and cytarabine consolidation</td>
<td>Phase III: CR rates and OS benefit; FDA approval April 28, 2017</td>
</tr>
<tr>
<td>PKC-412</td>
<td>ADC against CD33 with stable linker</td>
<td>HMA+ traditional induction</td>
<td>Significant CR/CRi rate in phase I trials of pts with CD33+ AML; FDA approval</td>
</tr>
<tr>
<td>Vadastuximab talirine</td>
<td>ADC against CD33 with stable linker</td>
<td>HMA+ traditional induction</td>
<td>Significant CR/CRi rate in phase I trials of pts with CD33+ AML; FDA approval</td>
</tr>
<tr>
<td>Enasidinib AG-221</td>
<td>IDH2 inhibitor</td>
<td>IDH2 mutated</td>
<td>Impressive single-agent activity (41% ORR in RR AML); FDA approval</td>
</tr>
<tr>
<td>Venetoclax ABT-199</td>
<td>BCL2 inhibitor</td>
<td>Ongoing investigation in newly diagnosed and RR AML</td>
<td>May have increased activity in patients with IDH mutations</td>
</tr>
<tr>
<td>Vosaroxin</td>
<td>Novel topoisomerase II inhibitor</td>
<td>RR AML</td>
<td>OS benefit in phase III trial when censored for alloSCT; mucositis notable AE</td>
</tr>
<tr>
<td>Gilteritinib</td>
<td>FLT3 inhibitor active against mutated TKD</td>
<td>FLT3-ITD or FLT3-TKD</td>
<td>Single-agent activity (CRc: 43%)</td>
</tr>
</tbody>
</table>

ADC = antibody drug conjugate; AE = adverse event; CRc = composite complete remission; CRi = CR with incomplete marrow recovery; FDA = US Food and Drug Administration; EFS = event-free survival; HMA = hypomethylating agent; MOA = mechanism of action; ORR = objective response rate; RR = relapsed/refractory.

CPX-351: Liposomal Daunorubicin and Cytarabine

- Cytarabine and daunorubicin are encapsulated in a fixed 5:1 molar ratio to the final dose of 1.0 mg and 0.44 mg, respectively.
- The two drugs interact with the copper gluconate/triethanolamine-based buffer and are contained in the aqueous space of a bilamellar liposome composed of phosphatidylcholine (DSPC).
- This gives the drug the deep purple color DSPG: cholesterol.

DSPC = distearoylphosphatidylcholine; DSPG = distearylphosphatidylglycerol.
Liposomal Daunorubicin and Cytarabine (CPX-351): Mechanism of Action

- Uptake into the hematopoietic niche (bone marrow)
- Liposomes persist in the bone marrow and are taken up by leukemia cells to a greater extent than by normal bone marrow cells in a murine model
- Liposomes undergo degradation, releasing daunorubicin and cytarabine within the intracellular environment9(7):741-750.

CPX-351 in High-Risk AML: Phase III Study Design

**Stratified by age (60-69 years vs 70-75 years), disease characteristics***

 Patients with previously untreated high-risk AML, 60-75 years of age, ECOG PS 0-2, ability to tolerate intensive therapy (n = 309)

**CPX-351 Induction, 1-2 cycles**
- 100 units/m²
- C1: Days 1, 3, 5; C2: Days 1,3 (n = 153)

**7 + 3 Induction, 1-2 cycles**
- Cytarabine: 100 mg/m²/day
- Daunorubicin: 60 mg/m²
- C1: Ara-C, 7 days; daun, 3 days
- C2: Ara-C, 5 days; daun, 2 days (n = 156)

**Consolidation† 1-2 cycles in patients with CR or CRi**

**Until death or 5-year follow-up**

**Primary endpoint: OS**
**Secondary endpoints: event-free survival, CR + CRi, 60-day mortality**

*Therapy-related AML; AML with history of MDS ± prior HMA therapy or CMML; de novo AML with MDS karyotype. †CPX-351 arm: 65 units/m², Days 1, 3; 7+3 arm: same dosing as reinduction (C2).

CMML = chronic myelomonocytic leukemia; ECOG PS = Eastern Cooperative Oncology Group Performance Status.

CPX-351: Efficacy

- CPX-351 demonstrated superior efficacy vs standard 7+3 induction.
- In patients undergoing transplantation, OS higher with CPX-351 (n = 52) vs 7+3 (n = 39): NR vs. 10.25 mos (HR: 0.46; 95% CI: 6.21-16.69; p = .0046)
- 30- and 60-day mortality rates lower with CPX-351 vs. 7+3

<table>
<thead>
<tr>
<th>Outcome</th>
<th>CPX-351 (n = 153)</th>
<th>7+3 (n = 156)</th>
<th>HR</th>
<th>Odds Ratio (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median OS, mos (95% CI)</td>
<td>9.56 (6.60-11.86)</td>
<td>5.95 (4.99-7.75)</td>
<td>0.69</td>
<td>NA</td>
<td>.005</td>
</tr>
<tr>
<td>Median EFS, mos (95% CI)</td>
<td>2.53 (2.07-4.99)</td>
<td>1.31 (1.08-1.64)</td>
<td>0.74</td>
<td>NA</td>
<td>.021</td>
</tr>
<tr>
<td>Response, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CR</td>
<td>37.3</td>
<td>25.6</td>
<td>NA</td>
<td>1.69 (1.03-2.78)</td>
<td>.04</td>
</tr>
<tr>
<td>CR + CRi</td>
<td>47.7</td>
<td>33.3</td>
<td>NA</td>
<td>1.77 (1.11-2.81)</td>
<td>.016</td>
</tr>
</tbody>
</table>

CI = confidence interval; HR = hazard ratio; NA = not applicable; NR = not recorded.

CPX-351 in Newly Diagnosed High-Risk AML: OS

ITT Analysis Population
Events, n/N
CPX-351 104/153
7+3 132/156
HR: 0.69
P = .005

Median Survival, Months (95% CI)
9.56 (6.60-11.86)
5.95 (4.99-7.75)

Months from Randomization

Survival (%)

ITT = intent to treat.
## CPX-351: Safety—Similar in the Two Arms

<table>
<thead>
<tr>
<th>Grade ≥ 3 AEs (≥ 5% Patients), n (%)</th>
<th>CPX-351 (n = 153)</th>
<th>7+3 (n = 151)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Febrile neutropenia</td>
<td>104 (68)</td>
<td>107 (71)</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>30 (20)</td>
<td>22 (15)</td>
</tr>
<tr>
<td>Hypoxia</td>
<td>20 (13)</td>
<td>23 (15)</td>
</tr>
<tr>
<td>Sepsis</td>
<td>14 (9)</td>
<td>11 (7)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>16 (10)</td>
<td>8 (5)</td>
</tr>
<tr>
<td>Respiratory failure</td>
<td>11 (7)</td>
<td>10 (7)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>11 (7)</td>
<td>9 (6)</td>
</tr>
<tr>
<td>Bacteremia</td>
<td>15 (10)</td>
<td>3 (2)</td>
</tr>
<tr>
<td>Reduced ejection fraction</td>
<td>8 (5)</td>
<td>8 (5)</td>
</tr>
</tbody>
</table>

**CPX-351: Prolonged Time to Recovery of Cytopenias Associated with CPX-351**

<table>
<thead>
<tr>
<th></th>
<th>Induction</th>
<th>Consolidation (At Least One Consolidation)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CPX-351 (n = 58) n (%)</td>
<td>CPX-351 (n = 48) n (%)</td>
</tr>
<tr>
<td><strong>Prolonged thrombocytopenia</strong></td>
<td>16 (28)</td>
<td>12 (25)</td>
</tr>
<tr>
<td><strong>Prolonged neutropenia</strong></td>
<td>10 (17)</td>
<td>5 (10)</td>
</tr>
<tr>
<td></td>
<td>4 (12)</td>
<td>1 (3)</td>
</tr>
</tbody>
</table>

Platelets <50,000 or neutrophils < 500 lasting past Day 42 in the absence of active leukemia

FLT3: What Is It?

Three hummingbirds

A cell surface tyrosine kinase (protein) commonly mutated in leukemia and associated with leukemogenesis and poor prognostic disease

Three teenagers

**Phase III RATIFY Trial of Midostaurin + Daunorubicin and Cytarabine in AML**

**Double-blind, placebo-controlled, randomized phase III study**

**Primary endpoint: OS (not censored for SCT)**

**Secondary endpoint: EFS**

### Induction* (1-2 cycles)
- Daunorubicin 60 mg/m² IV D1-3 + Cytarabine 200 mg/m²/d CIV D1-7 + Midostaurin 50 mg PO BID D8-21 (n = 360)
- Daunorubicin 60 mg/m² IV D1-3 + Cytarabine 200 mg/m²/d CIV D1-7 + Placebo D8-21 (n = 357)

### Consolidation (up to 4 cycles)
- Cytarabine 3 g/m² over 3 hrs q12h D1, 3, 5 + Midostaurin 50 mg PO BID D8-21 (n = 231)
- Placebo D8-21 (n = 210)

### Maintenance (12 cycles)
- Midostaurin 50 mg PO BID D1-28 (n = 120)
- Placebo D1-28 (n = 85)

*Hydroxyurea allowed for ≤ 5 days prior to induction therapy. BID = twice per day; CIV = continuous IV; PO = by mouth.

## Midostaurin: Efficacy (Based on RATIFY Trial)

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Midostaurin + 7+3</th>
<th>Placebo + 7+3</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>4-year OS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Uncensored*</td>
<td>51.4 (46.0-57.0)</td>
<td>44.2 (39.0-50.0)</td>
<td>0.0074</td>
</tr>
<tr>
<td>• Censored for SCT†</td>
<td>63.8 (56.0-71.0)</td>
<td>55.7 (47.0-63.0)</td>
<td>0.04</td>
</tr>
<tr>
<td><strong>Complete Response</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Any time</td>
<td>212 (59)</td>
<td>191 (53)</td>
<td>0.15</td>
</tr>
<tr>
<td>• CR1 only</td>
<td>239 (66)</td>
<td>211 (59)</td>
<td>0.045</td>
</tr>
<tr>
<td><strong>Median EFS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Overall</td>
<td>8.0 (5.1-10.6)</td>
<td>3.0 (1.9-5.9)</td>
<td>0.0025</td>
</tr>
<tr>
<td>• CR in induction/consolidation</td>
<td>11.3 (8.4-15.1)</td>
<td>6.1 (4.7-7.5)</td>
<td>0.0002</td>
</tr>
</tbody>
</table>

23% reduced risk of death in midostaurin arm

*HR: 0.77. †HR: 0.75. ‡Event: no CR within 60 days, relapse, or death. Stone RM, et al. *N Eng J Med* 2017;377:454-64.
Midostaurin Safety: Grade ≥ 3 Adverse Events with Statistically Significant Differences

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>Midostaurin  (n = 355)</th>
<th>Placebo  (n = 354)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anemia</td>
<td>329 (93)</td>
<td>311 (88)</td>
<td>0.03</td>
</tr>
<tr>
<td>Rash or desquamation</td>
<td>50 (14)</td>
<td>27 (8)</td>
<td>0.0008</td>
</tr>
<tr>
<td>Nausea</td>
<td>20 (6)</td>
<td>34 (10)</td>
<td>0.05</td>
</tr>
</tbody>
</table>

Remainder of adverse events were similar across the two arms.

Gilteritinib (ASP2215)

- Highly selective, potent oral FLT3/AXL inhibitor
  - Activity against FLT3-ITD activating and FLT3-D835 resistance mutations
- CHRYSALIS trial: phase I/II study (n = 252)
  - Primary endpoints: safety/tolerability, PK, and PD, antileukemic effects in patients with R/R AML
  - Population: heavily pretreated
  - 194 patients had a locally confirmed FLT3 mutation (ITD, n = 159; D835, n = 13; ITD-D835, n = 16; other, n = 6)
  - Diarrhea (16%) and fatigue (15%) were the most commonly reported treatment-related adverse events of any grade
  - 7 deaths considered possibly/probably related to treatment (all n = 1)
    - Pulmonary embolism, respiratory failure, hemoptysis, intracranial bleed, ventricular fibrillation, septic shock, and neutropenia

PD = pharmacodynamic; PK = pharmacokinetic; R/R = relapsed/refractory.
Overall Survival in FLT3+ Patients Treated with Gilteritinib (n = 191)

Gilteritinib ≥ 80 mg/day in FLT3+ patients
Median OS: 31 weeks (range: 1.7–61 weeks)
Median Duration of Response: 20 weeks (range: 1.1–55 weeks)
Median Time to Best Response: 7.2 weeks (range: 3.7–52 weeks)
Received FDA Fast Track designation Oct. 10, 2017
Phase III testing of oral gilteritinib 120 mg QD in patients with FLT3+ R/R AML after first-line therapy is underway (NCT02421939)

QD = once per day.
IDH2 and AML

Mutations in either IDH1 or IDH2 are observed in approximately 12% of patients with AML.
Enasidinib

- Selective oral IDH2 inhibitor, is the first and only drug to specifically target oncogenic IDH2 mutants
  - Mutational analysis is needed to determine whether patients have IDH2 mutations and therefore might benefit from enasidenib
- Enasidenib acts by inducing bone marrow differentiation and maturation rather than ablation
- Several months of treatment may be required before efficacy is observed
- Continuous daily enasidenib treatment was generally well tolerated and induced hematologic responses in patients with prior AML therapy failure

Enasidinib

- In a phase I/II study of enasidenib, the most common treatment-emergent adverse events were nausea (frequency: 48%) diarrhea (41%), and fatigue (41%); most of these events were mild or moderate in severity.
- Vomiting was managed with lorazepam, ondansetron, and prochlorperazine; diarrhea was managed with loperamide and diphenoxylate.
- Serious treatment-related differentiation syndrome was reported in 7% of patients and was managed with steroids.
- Permanent enasidenib withdrawal was not required.
- CR, CRi, or CR with incomplete hematologic recovery was 28% in patients who received 100 mg/day; median time to first/best response was 1.9/3.7 months.

Enasidenib

- Evolution of response during treatment of responding patients (n=71)

## Enasidenib: Safety—Grade ≥ 3 Treatment-Related Adverse Events

<table>
<thead>
<tr>
<th>Adverse Events</th>
<th>Enasidenib 100 mg per Day (n = 153)</th>
<th>All Patients (n = 235)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number</td>
<td>%</td>
</tr>
<tr>
<td>Hyperbilirubinemia</td>
<td>13</td>
<td>8</td>
</tr>
<tr>
<td>IDH differentiation syndrome</td>
<td>11</td>
<td>7</td>
</tr>
<tr>
<td>Anemia</td>
<td>10</td>
<td>7</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>8</td>
<td>5</td>
</tr>
<tr>
<td>Tumor lysis syndrome</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Leukocytosis</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Fatigue</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Nausea</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Lipase increased</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>

Gemtuzumab Ozogamicin

- First antibody-directed therapy (anti-CD33) for AML
  - FDA approved based on a phase II trial in 2000
- Five randomized trials where it was combined with standard induction chemotherapy in adults produced different results
  - Remission rates were not improved
  - Relapse was reduced in 4 of 5 trials with a significant survival benefit in two studies, AML16 and ALFA-0701
- Withdrawn from the US market in June 2010
- Re-analysis of previous trials led to the re-approval of GO on September 1, 2017 with a lower recommended dose

GO = gemtuzumab ozogamicin.
**Vadastuximab Talirine (Anti-CD33; SGN 33A)**

- Novel anti-CD33 ADC
- Coupled to pyrrolobenzodiazepine dimer 9DNA cross-linker
- More stable cross link
- Less affected by P-glycoprotein
- Although clinical trials looked to be favorable, Seattle Genetics has discontinued the phase III CASCADE clinical trial and suspended patient enrollment and treatment in all of its other vadastuximab talirine clinical trials due to patient deaths.

Vosaroxin: A First-in-Class Anticancer Quinolone Derivative

- Intercalates DNA and inhibits topoisomerase II
- Causes replication-dependent, site-selective DNA damage, G2 arrest and apoptosis
- Not a P-gp substrate
- P53-independent activity
- Minimal metabolism and creation of ROS
- Lower potential for off-target organ damage (cardiotoxicity)
- Low risk of drug–drug interaction
- VALOR trial translated to prolonged survival in relapsed/refractory AML, particularly in older patients
- No difference in 30- or 60-day mortality in patients > 60 years of age though higher rates of stomatitis and subsequent infections

BCL2 Inhibition in AML: Venetoclax

- Venetoclax is a highly selective, orally bioavailable BH3 mimetic that specifically targets BCL-2, but lacks affinity for BCL-XL and MCL-1.
- BCL-2 proteins play a critical role in mitochondrial mediated apoptosis.
- BCL-2 is overexpressed in AML.
- AML cells are primed for BCL-2 inhibition.

BCL2 Inhibition in AML: Venetoclax

- Venetoclax is a highly selective, orally bioavailable BH3-mimetic that specifically targets BCL-2, but lacks affinity for BCL-XL and MCL-1
- Phase II study: venetoclax 800 mg/day
  - High-risk relapsed/refractory AML (n = 30) or unfit for chemo (n = 4)
  - ORR: 19%
  - IDH1/2 mutations: 38% of pts
  - BH3 profiling consistent with on-target BCL-2 inhibition
  - Common AEs: nausea, vomiting, febrile neutropenia, hypokalemia

Phase Ib Study: Venetoclax + HMA in Patients with Newly Diagnosed AML Age 65 or Older

- N = 34; median age: 73 years; adverse risk: 41%
- Treatment: venetoclax 400 or 800 mg/day with either decitabine or azacitidine
- CR + CRi: 71%
- Treatment-emergent AEs:
  - Febrile neutropenia (38%), nausea (53%), diarrhea (41%), peripheral edema (35%)
  - 24/34 had delay/interruption for neutropenia or AE
  - 13 had delay of cycle 2 to allow ANC recovery
  - 23/34 discontinued treatment; 6 for allogeneic SCT
- Combination studies are currently ongoing and preliminary data so far shows significant improvement in response rates especially in the elderly patients, those with adverse cytogenetics and IDH-mutated AML

ANC = absolute neutrophil count.
Where to Go from Here? Emerging Therapies

<table>
<thead>
<tr>
<th>Mechanism of Action</th>
<th>Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein kinase inhibitors</td>
<td>• FLT3 inhibitors (quizartinib, gilteritinib, crenolanib)</td>
</tr>
<tr>
<td></td>
<td>• KIT inhibitors</td>
</tr>
<tr>
<td></td>
<td>• PI3K/AKT/mTOR inhibitors</td>
</tr>
<tr>
<td></td>
<td>• Aurora and polo-like kinase inhibitors, CDK4/6 inhibitors, CHK1, WEE1,</td>
</tr>
<tr>
<td></td>
<td>and MPS1 inhibitors</td>
</tr>
<tr>
<td></td>
<td>• SRC and HCK inhibitors</td>
</tr>
<tr>
<td>Epigenetic modulators</td>
<td>• New DNA methyltransferase inhibitors (SGI-110)</td>
</tr>
<tr>
<td></td>
<td>• HDAC inhibitors</td>
</tr>
<tr>
<td></td>
<td>• IDH1 and IDH2 inhibitors</td>
</tr>
<tr>
<td></td>
<td>• DOT1L inhibitors</td>
</tr>
<tr>
<td></td>
<td>• BET-bromodomain inhibitors</td>
</tr>
<tr>
<td>Mitochondrial inhibitors</td>
<td>• Bcl-2, Bcl-xL, and Mcl-1 inhibitors</td>
</tr>
<tr>
<td></td>
<td>• Caseinolytic protease inhibitors</td>
</tr>
</tbody>
</table>

**Where to from Here? Emerging Therapies**

<table>
<thead>
<tr>
<th>Mechanism of Action</th>
<th>Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapies targeting oncogenic proteins</td>
<td>• Fusion transcripts targeting</td>
</tr>
<tr>
<td></td>
<td>• EVI1 targeting</td>
</tr>
<tr>
<td></td>
<td>• NPM1 targeting</td>
</tr>
<tr>
<td></td>
<td>• Hedgehog inhibitors</td>
</tr>
<tr>
<td>Antibodies and immunotherapies</td>
<td>• Monoclonal antibodies against CD33, CD44, CD47, CD123, CLEC12A</td>
</tr>
<tr>
<td></td>
<td>• Immunoconjugates (e.g., GO, SGN33A)</td>
</tr>
<tr>
<td></td>
<td>• BiTEs and DARTs</td>
</tr>
<tr>
<td></td>
<td>• CAR T cells or genetically engineered TCR T cells</td>
</tr>
<tr>
<td></td>
<td>• Immune checkpoint inhibitors (PD-1/PD-L1,CTLA-4)</td>
</tr>
<tr>
<td></td>
<td>• Anti-KIR antibody</td>
</tr>
<tr>
<td></td>
<td>• Vaccines (e.g., WT1)</td>
</tr>
<tr>
<td>Therapies targeting AML environment</td>
<td>• CXCR4 and CXCL12 antagonists</td>
</tr>
<tr>
<td></td>
<td>• Antiangiogenic therapies</td>
</tr>
</tbody>
</table>

BiTEs = bispecific T-cell engagers; CAR = chimeric antigen receptor; DART = dual affinity retargeting; TCR = T-cell receptor

Case Studies in AML
Case #1: Presentation

- 36-year-old male diagnosed with AML in July
- WBC 84.4, Hgb 14, platelets 131,000 with 30% circulating blasts
  - NPM1+, FLT3-, IDH2+
  - Cytogenetics: deletion 16q
- ECHO EF 65%
- Exam was unremarkable

ECHO = echocardiography; Hgb = hemoglobin.
Case #1: Treatment

- July–December 2016
  - Admitted for G-CLAM Induction
    - GCSF + cladribine, cytarabine, mitoxantrone
  - Reinduction with G-CLAM (had MRD)
  - Consolidation with G-CLA

- Toxicities
  - Pancytopenia; transfusion dependent
  - Mucositis
  - Neutropenic fever
    - →Bacteremic with MDR E. coli→SEPSIS!

Neutropenic prophylaxis:
- ANC < 500: levofloxacin and posaconazole

HSV/VZV prophylaxis with acyclovir starts at induction

ANC < 500, and temp > 38.3 = admission

GCSF = granulocyte colony-stimulating factor; HSV = herpes simplex virus; MDR = multidrug-resistant; MRD = minimal residual disease; VZV = varicella zoster virus.
Initial Management of Suspected Sepsis

- **qSOFA**
  - AMS
  - RR > 22
  - SBP <100

- **SIRS criteria (>2)**
  - Temperature < 36°C or > 38°C
  - Heart rate > 90 bpm
  - RR > 20 breaths/min
  - WBC > 12,000 or < 4,000 cells/mm³

**“Soft” Indicators:**
- Do they look toxic?
- Change from baseline?
- What does the caregiver/family have to say?

AMS = altered mental status; qSOFA = Quick Sepsis Related Organ Failure Assessment; RR = respiratory rate; SBP = systolic blood pressure; SIRS = systemic inflammatory response syndrome.
Initial Management of Suspected Sepsis

1. Labs
   - Blood cultures (central line and peripheral)
     - Urine cultures if able
     - Venous lactate

2. If hypotensive and/or lactate > 4
   - Fluid bolus (30 mL/kg per hour); adjust for heart failure if needed

3. Antibiotics: within 3 hours (ideally within 1 hour)

4. Reassess: vitals and fluid response promptly
Timely Antibiotics Improve Sepsis-Associated Mortality

- **Critical Care Medicine 2006:**
  - Retrospective study of 2,154 patients with septic shock
  - Main outcome measure of survival to hospital discharge looking at the impact on morality of delays in initiation of effective antimicrobial therapy from the initial onset of recurrent/persistent hypotension of septic shock
  - *Time to initiation of effective antimicrobial therapy was the single strongest predictor of outcome*

Survival if antibiotics given in first hour → 80%

Each hour delay → decrease in survival of 7.6%

Case #1: Treatment

- July–December 2016
  - Admitted for G-CLAM Induction
    - GCSF + cladribine, cytarabine, mitoxantrone
  - Reinduction with G-CLAM (had MRD) – marrow → NED
  - Consolidation with G-CLA

- February 2017: BM biopsy shows **NED** by morphology/cytogenetics; he also has **NPM1-negative** and **normal cytogenetics** (i.e., resolution of 16q deletion)

- Consolidation #2 with HiDAC
  - Circulating blasts present on Day 22

HiDAC = high-dose cytarabine; NED = no evidence of disease.
Case #1: Treatment

- Decitabine + cytarabine
  - No response
  - → Relapsed refractory disease
- September 2017: intermediate dose cytarabine initiated with enasidenib on day 7
- Toxicities
  - Significant nausea, vomiting; anorexia

Enasidenib

Indication/FDA Approval: treatment of adult patients with relapsed or refractory acute myeloid leukemia with an IDH2 mutation

Toxicities
- Differentiation syndrome
  - 14% of patients may experience this life-threatening toxicity
- Appetite and taste changes, nausea/vomiting/diarrhea
- Tumor lysis syndrome
Case #2: Presentation

- 72-year-old male who presented to a community hospital with progressive fatigue that had been present for several years but had recently worsened substantially; he had not seen a medical provider for over 16 years and was taking no medications.

- At the time of his initial evaluation, he was febrile to 38.5, had flu-like symptoms and profound fatigue; labs were notable for Cr 1.35, LDH 629, albumin 3.1, INR 1.26, WBC 161,000, Hgb 6.8, platelets 13,000, 89% circulating blasts.

- He was admitted to the hospital for IV antibiotics, administration of hydroxyurea, and fluids while his workup was completed.

- Pertinent past medical history
  - Hodgkin disease age 51 treated with ABVD + radiation
  - Hypertension

ABVD = doxorubicin, bleomycin, vinblastine, dacarbazine; Cr = creatinine; INR = international normalized ratio.
# Tumor Lysis Syndrome: Risks and Management

## Risk Factors for Tumor Lysis Syndrome

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Details</th>
</tr>
</thead>
</table>
| **Tumor type** | - Burkitt lymphoma  
- Lymphoblastic lymphoma  
- Diffuse large B-cell lymphoma  
- ALL  
- Solid tumors with high proliferative state |
| **Tumor burden/extent of disease** | - Bulky disease  
- Elevated LDH (> 2 x ULN)  
- Elevated WBC (> 25,000) |
| **Renal function** | - Preexisting renal failure  
- Oliguria |
| **Baseline uric acid** | - Baseline uric acid > 7.5mg/dL |

## Patient Stratification by Risk

<table>
<thead>
<tr>
<th>Type of Cancer</th>
<th>High</th>
<th>Intermediate</th>
<th>Low</th>
</tr>
</thead>
<tbody>
<tr>
<td>NHL</td>
<td>Burkitt, lymphoblastic, B cell-ALL</td>
<td>DLBCL</td>
<td>Indolent</td>
</tr>
<tr>
<td>ALL</td>
<td>WBC ≥ 100,000</td>
<td>WBC 50,000-100,000</td>
<td>WBC ≤ 50,000</td>
</tr>
<tr>
<td>AML</td>
<td>WBC ≥ 50,000 (monoblastic)</td>
<td>WBC 10,000-50,000</td>
<td>WBC ≤ 10,000</td>
</tr>
<tr>
<td>CLL</td>
<td></td>
<td>WBC 10,000-100,000 treated with fludarabine</td>
<td>WBC ≤ 10,000</td>
</tr>
<tr>
<td>Other heme malignancies and solid tumors</td>
<td></td>
<td>Rapid proliferation with expected rapid response</td>
<td>Remainder of patients</td>
</tr>
</tbody>
</table>

CLL = chronic lymphocytic leukemia; DLBCL = diffuse large B-cell lymphoma; NHL = Non-Hodgkin lymphoma.

# Tumor Lysis Syndrome: Risks and Management

## Cairo-Bishop Definition of Tumor Lysis Syndrome

<table>
<thead>
<tr>
<th>Element</th>
<th>Value</th>
<th>Change from Baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uric acid</td>
<td>&gt; 8 mg/dL</td>
<td>25% increase</td>
</tr>
<tr>
<td>Potassium</td>
<td>&gt; 6 mg/L</td>
<td>25% increase</td>
</tr>
<tr>
<td>Phosphorus</td>
<td>&gt; 4.5 mg/dL</td>
<td>25% increase</td>
</tr>
<tr>
<td>Calcium</td>
<td>&lt; 7 mg/dL</td>
<td>25% decrease</td>
</tr>
</tbody>
</table>

**Clinical Criteria:** (lab criteria plus >1 of the following): increased creatinine (>1.5x ULN), cardiac arrhythmia, seizure

**Definition:** two or more lab changes within 3 days before or 7 days after cytotoxic therapy

## Management

- **Monitor tumor lysis labs** at least every 8 hours:
  - Uric acid
  - Potassium
  - Phosphorus
  - Calcium
  - Creatinine

- **Allopurinol**

- **Aggressive hydration +/- sodium bicarbonate**

- **Rasburicase**

---

Case #2: Presentation

- 72-year-old male with a creatinine 1.35, LDH 629, albumin 3.1, INR 1.26, WBC 161,000, Hgb 6.8, platelets 13,000, 89% circulating blasts
- ECHO: LVEF of 52%, Performance Status = 2
- Bone marrow
  - 90% myeloid blasts by flow
  - NPM1+, FLT3-
  - Cytogenetics: del(5q) and +8
    - MDS likely preceded presentation of AML

Past Medical History
- Hodgkin disease age 51 treated with ABVD + radiation
- Hypertension
- Hypercholesterolemia

LVEF = left ventricular ejection fraction.
## Case #2: Treatment-Related Mortality

<table>
<thead>
<tr>
<th>Performance status</th>
<th>Age</th>
<th>Platelet count</th>
<th>Albumin</th>
<th>Secondary AML</th>
<th>WBC</th>
<th>% peripheral blasts</th>
<th>Creatinine</th>
<th>TRM</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>72</td>
<td>13</td>
<td>3.1</td>
<td>Yes</td>
<td>161,000</td>
<td>89%</td>
<td>1.35</td>
<td>42</td>
</tr>
</tbody>
</table>

### TRM Score Interval

<table>
<thead>
<tr>
<th>TRM Score Interval</th>
<th>Patients below/within/above TRM Score Interval (%)</th>
<th>TRM Probability if below TRM Score Interval (%)</th>
<th>TRM Probability if within TRM Score Interval (%)</th>
<th>TRM Probability if above TRM Score Interval (%)</th>
<th>Patients below TRM Score Interval (%)</th>
<th>TRM Probability if below TRM Score Interval (%)</th>
<th>TRM Probability if within TRM Score Interval (%)</th>
<th>TRM Probability if above TRM Score Interval (%)</th>
<th>Patients above TRM Score Interval (%)</th>
<th>TRM Probability if below TRM Score Interval (%)</th>
<th>TRM Probability if within TRM Score Interval (%)</th>
<th>TRM Probability if above TRM Score Interval (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 - 1.9</td>
<td>0/20/80</td>
<td>-</td>
<td>1</td>
<td>12</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>67</td>
<td>10</td>
<td>15</td>
<td>15</td>
</tr>
<tr>
<td>1.91 - 3.9</td>
<td>20/20/60</td>
<td>1</td>
<td>2</td>
<td>16</td>
<td>8</td>
<td>0</td>
<td>39</td>
<td>0</td>
<td>15</td>
<td>15</td>
<td>15</td>
<td>15</td>
</tr>
<tr>
<td>3.91 - 6.9</td>
<td>40/20/40</td>
<td>1</td>
<td>7</td>
<td>20</td>
<td>20</td>
<td>1</td>
<td>21</td>
<td>18</td>
<td>18</td>
<td>18</td>
<td>18</td>
<td>18</td>
</tr>
<tr>
<td>6.91 - 9.2</td>
<td>60/10/30</td>
<td>3</td>
<td>7</td>
<td>24</td>
<td>42</td>
<td>2</td>
<td>14</td>
<td>26</td>
<td>26</td>
<td>26</td>
<td>26</td>
<td>26</td>
</tr>
<tr>
<td>9.21 - 13.1</td>
<td>70/10/20</td>
<td>4</td>
<td>12</td>
<td>31</td>
<td>55</td>
<td>4</td>
<td>9</td>
<td>35</td>
<td>35</td>
<td>35</td>
<td>35</td>
<td>35</td>
</tr>
<tr>
<td>13.11 - 22.8</td>
<td>80/10/10</td>
<td>5</td>
<td>20</td>
<td>41</td>
<td>70</td>
<td>6</td>
<td>5</td>
<td>53</td>
<td>53</td>
<td>53</td>
<td>53</td>
<td>53</td>
</tr>
<tr>
<td>22.81 - 100</td>
<td>90/10/0</td>
<td>6</td>
<td>41</td>
<td>-</td>
<td>85</td>
<td>9</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**TRM = treatment-related mortality.**


**TRM = death within 28 days from initiation of chemotherapy**
Case #2: Treatment

- He was enrolled in a phase III clinical trial with CPX-351: liposomal combination of cytarabine and daunorubicin
  - Induction chemotherapy was initiated at a dose of 100 u/m² on Day 1, 3, 5 over 90 minutes
  - Infusion was completed in the outpatient setting and was well tolerated
  - Toxicities
    - Pancytopenia/transfusion dependent
    - Nausea, fatigue, taste changes

CPX-351
Indication/FDA Approval: newly diagnosed tAML or AML with MDS-related changes

Toxicities
- Cytopenias
- Febrile neutropenia
- Rash
- Mucositis
- Nausea, vomiting, diarrhea/constipation

Standard transfusion triggers:
Hct < 25%, platelets < 10k
Case #2

- Day 28 bone marrow revealed persistent disease with 40% blasts
  - Reinduction chemotherapy: CPX-351 100u/m² on Day 1, 3, 5 over 90 minutes
  - Infusion was completed in the outpatient setting and was well tolerated
- Toxicities
  - Admitted with neutropenic fever
  - Pancytopenia/transfusion dependent
  - Fatigue, nausea, anorexia, and taste changes
Case #2

- Count recovery was delayed: Day 36 ANC > 500, platelets > 50,000
- Day 38 marrow was normocellular by morphology; flow cytometry was negative for abnormal blasts population; he remained $NPM1^+$
- 2 cycles of consolidation CPX-351 completed in July 2016→ lost to follow-up
- June 2017: called the office for an appointment because he felt poorly; a marrow showed 42% blasts

He got a full year from this approach!
Case #3: Presentation

- 62-year-old woman with a 3-year history of thrombocytopenia → progressed to pancytopenia
- WBC 49,000, Hgb 12.2, platelets 45,000, 76% circulating blasts, chemistries were normal with Cr 0.8, LDH 224, uric acid 4.8
- Bone marrow aspirate: 60% blasts
  - Cytogenetics: trisomy 8; NPM1+, FLT3+
- Exam was essentially unremarkable but she was very anxious
## Case #3: 2017 European LeukemiaNet Risk Stratification by Genetics

<table>
<thead>
<tr>
<th>Risk Category</th>
<th>Genetic Abnormality</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Favorable</strong></td>
<td>t(8;21)(q22;q22.1); RUNX1-RUNX1T1</td>
</tr>
<tr>
<td></td>
<td>inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); CBFB-MYH11</td>
</tr>
<tr>
<td></td>
<td>Mutated NPM1 without FLT3-ITD or with FLT3-ITD&lt;sub&gt;Low&lt;/sub&gt;</td>
</tr>
<tr>
<td></td>
<td>Biallelic mutated CEBPA</td>
</tr>
<tr>
<td><strong>Intermediate</strong></td>
<td><strong>Mutated NPM1 and FLT3-ITD&lt;sub&gt;High&lt;/sub&gt;</strong></td>
</tr>
<tr>
<td></td>
<td>Wild-type NPM1 without FLT3-ITD or with FLT3-ITD&lt;sub&gt;Low&lt;/sub&gt; (without adverse-risk genetic lesions)</td>
</tr>
<tr>
<td></td>
<td>t(9;11)(p21.3;q23.3); MLLT3-KMT2A</td>
</tr>
<tr>
<td></td>
<td>Cytogenetic abnormalities not classified as favorable or adverse</td>
</tr>
<tr>
<td><strong>Adverse</strong></td>
<td>t(6;9)(p23;q34.1); DEK-NUP214</td>
</tr>
<tr>
<td></td>
<td>t(v;11q23.3); KMT2A rearranged</td>
</tr>
<tr>
<td></td>
<td>t(9;22)(q34.1;q11.2); BCR-ABL1</td>
</tr>
<tr>
<td></td>
<td>inv(3)(q23.3) or t(3;3)(q23.3;q26.2); GATA2, MECOM (EVI1)</td>
</tr>
<tr>
<td></td>
<td>-5 or del(5q); -7; -17/ abnormal (17p)</td>
</tr>
<tr>
<td></td>
<td>Complex karyotype; monosomal karyotype</td>
</tr>
<tr>
<td></td>
<td>Wild type NPM1 and FLT3-ITD&lt;sub&gt;High&lt;/sub&gt;</td>
</tr>
<tr>
<td></td>
<td>Mutated RUNX1, Mutated ASXL1, Mutated TP53</td>
</tr>
</tbody>
</table>

Case #3: Treatment

- Standard 7+3 induction as an inpatient; no infusion-related or cerebellar toxicities
- Discharged on day 6 after completion of therapy
  - Early discharge criteria: age < 65, within 20 minutes of the medical center, 3x/week labs, caregiver with patient
- Started midostaurin 50 mg PO BID on days 8-21
- Toxicities
  - Pancytopenic; transfusion dependent
  - Nausea, mild mucositis
  - Cellulitis (face) requiring readmission on day 15

Midostaurin

Indication/FDA Approval: adult patients with newly diagnosed FLT3+ AML
- Given in combination with standard 7+3 (cytarabine and daunorubicin) induction followed by cytarabine consolidation

Toxicities
- Nausea/vomiting
- Febrile neutropenia
- Mucositis
- Hyperglycemia
- Interstitial lung disease
Case #3: Treatment

- Day 28 marrow: no evidence of residual/recurrent AML
- Consolidation with HiDAC 3 g/m² Day 1, 3, 5
  - Early discharge on day 6
- Midostaurin 50 mg PO BID on days 8-21
- Toxicities
  - Nausea, anorexia
  - Neutropenic fever
  - Pancytopenia; transfusion dependent

October update:
Arrived to the BMT service for a planned matched unrelated peripheral blood stem cell transplant in first CR
HCT Comorbidity Index Calculator

HCT-CI is a comorbidity index that comprises 17 different categories of organ dysfunction:

- Arrhythmia
- CV disease
- IBD
- DM
- Cerebrovascular disease
- Psychiatric disturbance
- Hepatic comorbidity
- Obesity
- Infection
- Rheumatologic comorbidity
- Peptic Ulcer
- Renal disease
- Pulmonary
- Prior solid tumor
- Heart Valve
- Age

- It provides information with regard to the overall as well as non-relapse mortality risk a patient is likely to experience after hematopoietic cell transplantation

- It can be an important decision-making instrument for choosing appropriate conditioning regimens for patients with acute myeloid leukemia, myelodysplastic syndromes, and those with lymphoma or chronic lymphocytic leukemia

- Does NOT take the place of a formal transplant consult

CV = cardiovascular; DM = diabetes mellitus; IBD = irritable bowel disease.
Summary

- Many tools are now available to identify prognostic and risk factors that will affect treatment decisions—use them!
  - Cytogenetics (low, intermediate, and high risk)
  - Treatment-related mortality indicators (TRM)
  - Transplant comorbidity index (HCT-CI)
  - Genetic risk stratification (ELN)
- Increasing number of targeted treatments are becoming available that are especially useful when using the available tools
  - FLT3 inhibitors
  - IDH2 mutations
- Keep toxicities in mind
  - Pancytopenia
  - Tumor lysis syndrome
  - Sepsis
  - Differentiation syndrome
Your 74-year-old patient was just started on enasidenib, an oral mIDH2 inhibitor that promotes myeloid differentiation of leukemic blasts. He complains of shortness of breath and fever; on auscultation, you hear crackles and note he has pitting ankle edema and a temperature of 101.7 degrees. You suspect:

1. He has neutropenia and has contracted pneumonia
2. He has IDH inhibitor–associated differentiation syndrome
3. He has a cardiac history and needs a cardiac consult
4. He has retinoic acid syndrome
5. I’m unsure
Question #2

Your patient has been diagnosed with relapsed AML after initial treatment. Testing with next-generation sequencing has revealed an IDH2 mutation. What is your choice of treatment?

1. Enasidenib
2. Gemtuzumab
3. Midostaurin
4. Quizartinib
5. I’m unsure
Question #3

Which recently approved anti-CD33 monoclonal antibody has a history that underscores the importance of examining alternative dosing, scheduling, and administration of therapies for patients with acute myeloid leukemia (AML), especially in those who may be most vulnerable to the side effects of treatment?

1. Ofatumumab
2. Rituximab
3. Gemtuzumab ozogamicin
4. Ipilimumab
5. I’m unsure
Question #4

You have a 67-year-old male patient with FLT3-positive AML who received a standard dose of cytarabine and daunorubicin 1 year ago and is now presenting with a relapse. The phase I/II CHRYSLALIS study results were the first demonstration of molecular response to a FLT3 inhibitor in AML. Your patient may be a good candidate for the ongoing registrational ADMIRAL trial for patients with relapsed/refractory FLT3+ AML. Which therapy is being studied in this trial?

1. Enasidenib
2. Quizartinib
3. Midostaurin
4. Gilteritinib
5. I’m unsure
Question #5

Patients receiving high-dose chemotherapy for the treatment of AML are at an increased risk of neutropenic fever and sepsis. So timely initiation of antibiotic treatment is critical. A 2006 study of 2,154 patients showed a survival rate of 80%, if antibiotics are administered within how long after documented hypotension?

1. 24 hours
2. 3 days
3. 1 hour
4. 12 hours
5. I’m unsure
SANDY     Good evening, everyone. We are proud of you for staying awake this late on a school—oh, it’s not a school night, is it? It’s a weekend. So, we’re so glad you could join us for this accredited program tonight called “A Deeper Dive into Advances and Future Directions in Treating Patients with Acute Myeloid Leukemia.” It is accredited by the Annenberg Center for Health Sciences at Eisenhower and to claim your credit, please follow the instructions on the sheet you received this evening. If you didn’t receive an instruction sheet, let a staff member know and they can provide one for you.

We’re going to get started. I’m Sandy Kurtin. You may have heard me earlier today. I am a nurse practitioner at the University of Arizona Cancer Center. And I’m going to let Gabe introduce herself.

GABRIELLE My name’s Gabrielle Zecha; I’m a PA at the Seattle Cancer Care Alliance in the University of Washington Medical Center.

SANDY     All right. And with that, let’s get started. Let me ask, first of all, how many of you attended the session with Dr. Artz and Dr. Ridgeway? Okay, that’s helpful. I’m going to try to really put a little different twist on this so we’re not—not that reinforcement isn’t a good thing, but I don’t want to make it repetitious.
I’m going to take the time to go through a little bit of the science and the A to Z of acute leukemia, so we’re going to start really talking about those things. We’re going to go through a little bit about the disease state. Acute leukemias were first noted by Dr. Virchow in 1845, so these have been around a long time. And yet, we’ve had the same therapy for a very long time since then, so it’s exciting to be up here to talk about some of these new developments.

There are roughly 21,000 cases each year. Unfortunately, about half of the people die, so it’s never good when you see incidence in death rates being that close together. Median age at diagnosis is 68, so this is really important to keep in mind. And the 5-year overall survival for all comers is really pretty dismal; when you think about malignancies, really only 27 percent. In terms of new cases and deaths, again, you can see how those look and how close those are in proximity. That’s never really what we’re looking at. Median age at diagnosis, 68. Most of the people who are dying are a little older than that, so the median age at death is 78.

Most of the time, we don’t know what causes this; it’s more common in older patients. We get hematopoietic senescence, so as we get older, the organs don’t repair themselves readily and you can have abnormalities occurring as a result of age itself, mutagenic and genotoxic stresses.

We heard a lot about the driver mutations, but also acquired mutations in many of the talks that we’ve heard so far. And then, we cause it sometimes ourselves by treating people for other diseases, and this is becoming more and more of a problem. The big players here are therapeutic alkylators, so drugs like
cycloheximide, which is probably still today one of the most common drugs that we administer; the topo II inhibitors, which include things like the anthracyclines, mitoxantrone, and etoposide; and then, doing stem cell transplants. So we have secondary leukemias, treatment-related AML, or treatment-related MDS as a result of prior therapies in these patients with solid tumors.

There is a smaller number of patients who have ALL that then, as a result of their long-term therapy, develop AML. We see environmental and occupational exposures; one of the big culprits is benzines. Benzine is also the primary agent in tobacco, so we now have clear data to say that tobacco smoke is related to bone marrow disorders, and the myeloid diseases are not an exception.

We also see this phenomenon of AML that comes out of antecedent hematological malignancies—the most common one being MDS—also, representing a unique challenge, and then, very rare inherited congenital abnormalities.

Most of the time, onset here is pretty abrupt. I was at an advocacy meeting and talking to patients, and it's like you just get plucked out of your life. It's like boop, here you go; boom, right? And your life changes forever; it's very abrupt. Things have to happen very quickly. People often present with pretty dramatic symptoms. In some cases, we see skin involvement, so I'll show you a couple of pictures in a minute.

It's really important to talk about the history of the disease and how it presents and what kinds of things that you're seeing, so you get a little sense of
the tempo of the disease. AML, just like many of these hematological malignancies, is pretty heterogeneous, and you can really get a sense of how that’s going to go by getting the sense of tempo. How long have they had these symptoms? Did it just happen a week ago or has this been cultivating over the course of several weeks? So, really looking at that carefully; looking at their comorbidities and medications is going to be critical as we initiate therapy, and needing to really take care of that whole patient and then doing a very good, thorough physical exam; full skin, the whole thing, orifices, everything.

Laboratory analysis is really critical in these patients as well. Patients with AML can present in active tumor lysis just from the disease itself, so we’re going to want to do a baseline screen, including the uric acid and an LDH, which is not part of the complete metabolic panel; it’s on a different instrument. The other thing to note is the LDH upper limit normal varies by institution, so there is no universal norm and that’s important to know. Sometimes you’ll see patients presenting with thermolysis, so we’re going to want to look for that too.

In the case of APL, which we’re not going to really talk about, some of these people present with coagulopathies and active DIC. So if there’s some, but they’re really just covered in bruises and they have like a bloody nose, you’re going to be more worried about something like APL and we’re going to want to do a full coag workup.

Lumbar punctures are absolutely necessary in ALL and anybody with CNS symptoms. With suspected myeloid malignancy, you’re going to also want to do that. You’re going to look for underlying viral entities. And then if they’re young,
you want to make sure they’re not pregnant. This has happened before and that’s always very, very difficult.

Then you need the diagnostic bone marrow biopsy and aspirate, and this is really critical. And if you attended the session earlier with Dr. Artz and with Jean Ridgeway, you know that we have to ask the right questions. So when you’re doing that marrow you’ve got to say, “What is my question? What are the things I might be looking for?” And make sure that you get a good sample and all of the different tubes that are necessary to answer any of those possible questions. It’s really important to check with your team and really find out what do we think it might be? It’s better to pour a little extra than not have enough. So, getting a good aspirate with spicules and then an adequate core—very critical to being able to answer the question.

Some of the things we want to know: we’re going to do metaphase cytogenetics, which is basically those 20 metaphases. That’s what you get in the bracket when you read a cytogenetic report; it’ll say 16 out of 20 or whatever. If there’s something that’s greater than two metaphases, it’s considered non-random, so it’s real. There are transient cytogenetic abnormalities that happen in these malignancies just because there’s so much going on. If it’s less than two metaphases, that may not be real. We’re going to screen for these genetic mutations.

It used to be that we asked for NPM1, CEBPA, RUNX1, and c-Kit, which is not on there, and those have now been trumped by some of these others: TP53, ASXL1, and IDH2. We’re also going to ask some of the other questions in flow
cytometry now looking at CD33, which comes in the immunophenotyping. If you are concerned about APL, we’re going to do PML RAR-alpha; that’s a PCR test. And, also, if there’s any concern for underlying CML, that if turned into blast crisis, you’re going to do BCR-ABL. It’s really important to just get a sense, and we do that from the history and the baseline laboratory analysis to get a sense of what is the question?

We're then going to do some diagnostic radiology. A baseline chest x-ray is always critical so that we have something that we know we started with. In case people develop symptoms, we can compare it to baseline—baseline EKG, MUGA, or echo—because anthracyclines are still very much a part of induction therapy in these patients.

If we’re concerned about CNS disease or hemorrhage, you want a non-contrast CT. If you’re worried about leukemic meningitis, then you need an MRI. Part of what we talked about in the imaging sessions is, again, what is your question? And if you’re in doubt, call Radiology and say, “Here’s what I’m worried about.” And they’re going to say, “Here’s what you want to order,” right? So we’re not wasting time or money or unnecessarily exposing patients to the contrast dye and the radiation.

All of these people are going to need lines, so depending on what the possibilities are, what their platelets are, deciding what that line might be may vary. This is what the cutaneous manifestations could sometimes look like, and people that have monocytic predominance, it’s a tissue infiltrating. They get these very hypertrophic gums to where they can hardly close their lips.
sometimes and that’s pretty telling. That actually can be good; that subtype of AML can actually be treated pretty effectively.

And then there are people who get leukemia cutis. And I’ve seen actually a lot of people who have relapsed with leukemia cutis where you start to see these bumps coming up into the skin, and that’s really the first sign of relapse before we start to see some of the changes in their count. Always really important in these patients to do a good skin exam, a good oral exam.

We heard a little bit about the revision of the 2016 World Health Organization classification system. This is really getting complicated. It is not going to get any easier, so we’ve just got to keep hearing this stuff, to like strap on, hold on tight. It’s like a bronco ride, right? Don’t get bucked off. We can do it, right? We have to be able to understand this; it’s very important in understanding prognosis. And we have to somehow be able to explain it to colleagues and to patients at some level.

They’ve broken this up into germline mutations with a predisposition for organ dysfunction and platelet disorders or myeloid neoplasm with predisposition and other organ functions. There’s a bunch of these that have these molecular attributes attached to them.

And then you have AML with recurrent genetic abnormalities. And this is where you heard earlier that not only do you see the cytogenetic abnormality, but you see the associated molecular abnormality, and to really be able to fully characterize that patient’s disease can take some time. These are not things that come back quickly, and that can be a challenge.
We’ve heard about AML with myelodysplasia-related changes. These are the people—you know, and these happen a lot. You have older patients, they come in, they look like they have acute leukemia de novo, like just leukemia. You treat that and then what’s left is actually underlying MDS, and that changes the game completely. And then, of course, every category has a not otherwise specified. And then you get to this. This is how complicated this is getting. You’re looking at these subtypes of these molecular attributes and you’re basically carving out these little niches for these diseases. I will say that we don’t completely understand all of these niches, but we’re getting to a point where it’s really becoming more and more clear.

So we use this for risk stratification. We want to know what are the factors associated with poor risk? How aggressive are we going to be with that patient? If they have AML from an antecedent hematologic malignancy, the prognosis is very different than if it’s de novo. And certain types of de novo are considered like a core-binding factor AML. Translocation (8;21) is potentially curable. I’ve had people actually cured with standard therapy. You don’t find those very often. Most people will not be cured without an allogeneic stem cell transplant. You can't have your own marrow when you have a myeloid malignancy. Well, you could, but it won’t work, so why do it? You’ve got to have an allo in any myeloid malignancy.

So we look at all of these things to try to identify risk. We look at age alone. Age alone should not be a determining factor when—you know, those of you who attended the lecture earlier with the TOPS Clinic, really an innovative
way to look at—we tune people up so they’re strong enough to be able to undergo this more aggressive therapy. But this is really just looking at this different AML based on age, and the difference that age alone makes in those patients when you look at 15 through 59 on the left there and then on the right age greater than 60. So even though we say age alone should not exclude treatment, it does matter in these patients.

They take all this information and they develop these risk categories. And here’s the translocation (8;21) that’s called core-binding factor; that’s considered a favorable prognosis. But then you get into these mutated or unmutated \textit{NPM1} and \textit{FLT3}, and whether it’s wild type or unmutated becomes very important, and I’ll show you some examples.

Here’s wild-type \textit{NPM1} and \textit{FLT3} internal tandem, or ITD high expression, and so, the combinations of certain things also matter. This is becoming very complicated and even the anatomopathologists are struggling to really embrace all this. It just was released really less than a year ago. It says 2016, but we really didn’t get them.

Now this is a very eloquent body of work. This is Elli Papaemmanuil who is at Harvard and she has developed this extraordinary project. And we have an international working group for MDS; we have an international working group for MDS/MPN crossover; and then we have an international working group now in AML looking at bringing together samples from all over the world to be basically mapped and profiled. And so, this is just the beginning of this work; it’s really extraordinary.
But what you can see here, the predominant driver mutations in AML, and what this tells us is we know there may be an opportunity there as a target for therapy. And some of these already are. And we know TP53 is never good; it doesn’t matter what you have, it’s bad, bad, bad. TP53 is 17p, that’s your surveillance gene. If that gene is abnormal, you can't surveil your own abnormal cells. So 17p, TP53 mutations or deletions are bad regardless of what it is. And you can see if you match those up with other abnormalities on the other axis there, that one line down there has a lot of problems.

This is where you start to look at matching these up. So, here’s TP53, NPM1, and FLT3, and just by looking at whether it’s a complex karyotype. A complex karyotype is greater than three abnormalities on metaphase cytogenetics, so your cytogenetics are basically your blueprint. If you have a bad blueprint, you are not going to make a normal cell. If you have a paragraph of cytogenetic abnormalities, that’s bad, that’s really bad. So, complex is just greater than three, so if you add a complex karyotype to the presence of TP53, look at the difference that makes in that outcome. So if TP53 by itself is bad, but you add to that other abnormalities, and that makes it that much worse.

Similarly, you heard about NPM1, whether it’s wild type or mutated, plus or minus the DNA methyltransferase or DMT3 mutation, and look at the difference that that makes in survival. So we’re beginning to understand why there’s patients that do good or well and then people that just do very poorly and they don’t respond and they don’t do well even with induction therapy.
Then we have our therapy-related myeloid neoplasms, and I talked a little bit about this. Alkylators are bad players. There’s different times of onset; this is really devastating for people. So we see a lot of patients who have had R-CHOP, right? It’s still the standard of care for diffuse large B-cell lymphoma. And they started developing cytopenias late in the game—you know, 8, 10 years out—and it’s not their lymphoma coming back; they have treatment-related AML or MDS, and that’s devastating.

Probably even more devastating are the patients that we’re beginning to see with breast cancer and even ovarian cancer where we’re having these topo II inhibitors and they’re relapsing or they’re developing treatment-related AML 2 or 3 years out from the treatment of their primary therapy for their other malignancy and they also have a very poor prognosis. So it’s good now, but we have some options for these patients. It’s really devastating for them.

This is how it looks: treatment-related AML, treatment-related MDS, secondary AML. You see both molecular and cytogenetic abnormalities that are most common. And, again, TP53 is right up there at the top. The other thing I say is seven is not lucky in MDS, right? Anything that’s a minus seven in MDS, those people tend to convert to AML much more frequently than people who do not have that abnormality. But you can see here, again, we have common players here. FLT3, TP53 are right there up at the top.

So what are we going to do for these people? Well, this is a disease that you do not watch and wait, right? So, generally, treatment is immediate. The struggle that we face right now is that, you know, we need all this information and
it matters and you want to get the diagnosis right, and doing that morphologically by itself now is really not enough. And cytogenetics, even in the best of situations, usually take about a week. Some of these molecular studies if they’re send-outs can be 10 or 14 days, so it’s really our challenge to do these in an expedited way.

There was a study 7 years ago, Dr. Nickel Securus and others, that looked at elderly AML and found that really you could wait at least a week or more and it didn’t really change the outcome for those patients. So there’s nothing wrong in the older population in particular. If you’re really worried about an antecedent hematologic malignancy or one of these other subtypes to give it some time and supportive care, get lines put in, and do all the diagnostics, use hydroxyurea if you need to control their blasts. So you get the right information before you actually decide on treatment. The big question always is are you eligible for transplant? And sometimes that becomes really the determining factor in how aggressive we are up front.

Induction therapy is still our primary goal; we want to suppress that marrow, clean it out; hopefully, then what grows back is healthy. We’re going to do consolidation because even if we do a day 14 marrow and there’s no evidence of disease, we know that at a molecular level, those cells are going to be there. And so, we are now moving into an MRD-negativity phase with AML, much like we are in other hematological malignancies where you’re saying at a molecular level “I cannot see any abnormalities.” That’s something that’s really
being pushed and really being part of what we decide on whether somebody can actually go to transplant.

The last thing you want to do is take someone to transplant with active disease. They just don’t do as well and they’re really much more at risk for a relapse. So, then we say, “Okay, if the end game is really an allogeneic stem cell transplant…” This is work that has primarily come out of Washington, and I know Gabe has a couple slides, as well, on the case. But the deal is here to really look at all the organ systems and say are they up to snuff or not? Are they otherwise healthy or not?

You can see a whole list where you get a score of one here and then you get down into a score of three. So, prior solid tumor, heart valve disease, heart valve disease, severe pulmonary disease, or moderate or severe hepatic disease gets you a score of three all by itself. So when you think about that, then they said, “Okay, that’s fine, now this is evolving.” Originally that work was done in 2007.

And then, they started to say, “You know, let’s look at age. Does that matter?” Well, we saw the age curves, and so they said, “Let’s do this composite score where we add age and then we’re going to add in cytogenetic factors and we’re going to categorize them as favorable, intermediate, or adverse.” And you saw that list. So now they’re saying, “All right, we’re going to account for more of the disease attributes; we’re going to add age; we’re going to look at organ function collectively, and how does that look?” So if you see here, this composite score of greater than three, it’s associated with inferior outcomes. You can get
that simply by having valvular heart disease or you can get it because you are of an older age and you have adverse cytogenetic abnormalities.

So the way you get to that score might be different, but either way it’s unfavorable. It’s becoming more and more precise in really estimating risk and making a proper decision about how aggressive should we really be with the individual patient?

And then, this is just looking at adding that, again, altogether in a different way where you’re adding the age score in to the composite score and then, so you’re getting up to a score of five by doing that. And you can see the differences that that makes. So really, a new way of looking at things.

And then, they said, “Okay, well, that’s all great. So, now we want more.” Now we’re going to say if they present with a low albumin, what does that—that’s always worrisome for me. People that have been in the hospital for 21 days and their albumin is 1.9; that’s never good. I worry about those people; they are not going to do well. It’s going to be really hard to treat them again. Their platelet count being low, their LDH level being high, and so they’ve added that into the factor, and then, ultimately, come up with this total composite score with all of those other items and look at how those break out. It’s really becoming an art to assess risk. It’s no longer just cytogenetics, it’s no longer just age, it’s all of this together: organ function, comorbidities. And we need to do this work to really do the right thing for the patients and not over-treat and not undertreat.

So with all of that, and you finally get through that, you’re like, “Woo, that was a lot of work.” And then we’re going to say, “Okay, if you’re medically fit and
you don’t have one of those higher scores and we want to do induction, the
standard of care is still 7+3." But one of the first questions we’re going to ask is,
“Are you FLT3 positive or not, mutated or unmutated?” That’s going to make a
difference in whether we add something to induction with 7+3, specifically
midostaurin, at this point. And, ultimately, our end game is still are you eligible for
a transplant? Because most standard therapy other than core-binding factor AML
is not curative with the exception of APL in some cases, which is really treated in
an entirely different way.

If they’re not FLT3 positive, then you’re going to really go back and say,
“How fit are they?” You know, there’s levels of fitness and what can they handle?
If they have secondary AML, you’re going to think about using the liposomal
CPX-351 or daunorubicin and cytarabine for their induction. And in some of the
elderly AML where they’re marginally robust, then you may treat them with a
hypomethylating agent similar to what you would do for MDS.

Standard of care is still 7+3. We still do the day 14 marrow, we want it to
be empty and their counts aren’t bottomed out. We get sad because we don’t
think it’s working. We’re going to say if they have residual disease or not. If they
have residual disease, they need reinduction. If they then are negative, we’re
going to do a recovery marrow and hope that all those cells are healthy and
there’s no residual disease then.

If they fail two inductions, that’s really bad news; salvage therapy is
marginally beneficial in these patients. I think what we are seeing now is there
are people—we had a conversation with somebody that said they’re beginning to
not even do the day 14 marrow because what’s it going to do for you, right? It’s become a habit for us. And, ultimately, what you want to know is when the marrow recovers, is there leukemia there? And you’re going to know whether they bottomed out their counts or not. There are people that are getting away from this day 14 marrow, which is probably good for patients, just to know that.

If they’re medically unfit, then we really need to say, “What’s the tempo of that disease?” If they’ve got 76% blasts and it’s climbing, that’s one scenario. There’s those people that are just tiptoeing along; their blasts are just pretty stable and they’re not really that aggressive. That’s going to mean something different, and that’s where we may use something like azacitidine. Or always in these patients, we want to consider a clinical trial.

7+3 has been around for eternity; 44 years later we’re still doing it. This is 1973 Yates and colleagues. It’s still the standard of care for patients with newly diagnosed acute myeloid leukemia. We have many of these trials. As you saw some of the examples in the algorithm, they’re adding something else to that to optimize these other targets that are being identified as prognostic indicators. There are the patients who do well with this low-intensity treatment, so even azacitidine. Azacitidine is actually the only drug that has survival data. Many people will argue that the trial designed for the decitabine was just not done well, and so, there are people that prefer one or the other. There’s still people that use low-dose cytarabine. My experience has been it lowers their counts, but then they just become pancytopenic and you’re not really adequately controlling the
leukemia. There are instances where we just give that supportive care and we control the blasts with hydroxyurea and maybe transfusion support.

Let’s talk briefly—and I know you’ve heard some about these drugs, so I’m just going to touch just on some of the points that maybe we didn’t cover. This is just a list of all those, and you can see that they have different mechanisms of action. We have the FLT3 inhibitors, some off-target affect to c-Kit; PDGFR, which is platelet-derived growth factor VEGF actually—and marrow’s a very vascular place and VEGF plays a really big role in the balance of apoptosis program, so death and depression of disease. When people are progressing, that apoptosis program is not working and progression takes over. A lot of that has to do with VEGF.

We mentioned the IDH2 mutation and the IDH2 inhibitor and axitinib or AG-221. Venetoclax not approved, but there are trials going on. And then, we’re going to talk about a couple of the other drugs.

So, you heard about the purple drug, like this daunorubicin. And, actually, why it’s purple is there’s a copper compound in there and you combine that copper compound—there’s little dots in there—with some of the lipid structure and it creates this very deep purple color. So, it’s now forever more the Barney induction, according to Dr. Harvey. But it’s a very purple drug.

And there are different dosing regimens than 7+3, but it’s still a combination of daunorubicin and cytarabine, so the toxicity profile, the things that we are worried about in 7+3; cardiac function, vesicant, still apply. Even though it’s compounding in a different way, the drugs are essentially the same, they’re
just in this different molecule. So, you have to treat it with the same respect and safety, and I’ll skip over that.

Here’s the trial design—which I think you also saw earlier—randomizing to a standard 7+3 or the CPX-351. And you can see that it’s dosed in induction days 1, 3, and 5. And then, in cycle 2 just days 1 and 3. So, consolidation, which is very different in standard 7+3 when you get 3 days of daunorubicin and you get 7 days of continuous infusion of cytarabine.

These are the outcomes, and you saw those survival curves that were presented earlier, so there was an overall survival advantage in the patients getting the liposomal compound. And this is basically that survival curve favoring the patients doing liposomal versus standard 7+3, which is in that golden rod color. It did make a difference for these patients. And the majority of these people were older and had this high-risk AML, which either had antecedent hematologic malignancies, specifically MDS, or treatment-related AML. So this is pretty impressive in that high-risk group, which don’t really do well with standard therapy historically.

Again, in the side effect profile, very much the same. The one thing I would mention that Dr. Harvey didn’t mention and that’s different: our paradigm has always been day 14, day 28, right? And treat as soon as the count’s recovered with consolidation. It’s keep the intensity—go, go, go. What you do find in this drug are these prolonged cytopenias and particularly platelets where it may take you 7 or 8 weeks for that patient to recover. If you go back and you say, “Okay, you know what? They actually did better with overall survival.”
And a slide I don't have on here is a greater depth of response, so there were more CRs. Then, you can say to yourself, you know what? We have to think of this in a different way and move away from the standard paradigm of day 14, day 28 because we may not be able to retreat them until week 7 or 8. And that makes people freak out because we're so used to this 14 and 28 that we've been doing for 44 years. So we have to rethink our paradigm in a lot of these new drugs.

These prolonged cytopenias can mean that you can’t do consolidation at the standard day 28. And that’s okay with that drug because that’s how it behaves. It’s like a somal; it stays in there. It gets into the marrow space more efficiently because of how it works and it exposes those cells over a longer period of time.

Now, here’s FLT3. I made this slide in whatever, 2004? And so FLT3. A cell surface tyrosine kinase protein commonly mutated in leukemia, which is associated with leukemogenesis. Basically, as you heard, it’s constitutively on; the gas pedal’s to the floor all the time making these abnormal cells. And it’s associated with a poor prognosis, so that would be the right answer.

This is the RATIFY trial; we heard a little bit about this. This is midostaurin, a FLT3 inhibitor, added to 7+3 in newly diagnosed AML. It is not intended as a single agent and it is intended to be given with 7+3. And you can see that there was a statistically significant difference for your overall survival and increased repeat responses.
Adverse events: not surprising anemia, but there were some rashes and some with dusk formation in the midostaurin arm compared to the placebo arm. And nausea was pretty equivalent across the two groups.

This is a newer FLT3 inhibitor not yet approved, gilteritinib. It’s highly selective, potent FLT3 and AXL inhibitor. This CHRY Salis trial was a phase I/II study, so 252 patients, which is a pretty good number for AML. Primary endpoints: safety and tolerability and pharmacokinetics/pharmacodynamics; that’s what PK and PD mean. And they found that the drug is taken up and has benefit. They do have seven deaths on this trial, so it is something that’s being moved forward, but carefully.

Then this, again, is showing the difference in the outcome in overall survival in the patients receiving that drug. And, again, looking at dose finding for what’s going to be the appropriate dose to move forward with the phase III trials.

We talked about IDH2 in AML, so IDH2 or isocitrate dehydrogenase. This is part of your Krebs cycle. You’re like, “Oh, my God, don’t make me do the Krebs cycle; not now!” But it has a lot to do with how cells develop normally or don’t. And what ends up happening in the presence of mutation is you get this methylation, and we know that hypermethylation is leukemogenic. We also know that there’s impaired cellular differentiation, and what that means is cells don’t grow up normally; they can’t mature and do the things that they’re intended to do.

Itacitinib we’ve heard about, again, a couple times yesterday and then again today; it’s a selective oral IDH2 inhibitor first in class. And we do need to
know—and this is why it’s so important when you’re first diagnosing a patient—to be sure that you’re answering all the questions.

The other thing that’s really important is that this drug is approved in relapse disease. The disease you start with is not the disease you’ll end up with, right? So, you may have been IDH2-negative initially, but you can acquire mutations in some cases, and so we really want to be able to answer that question at each point of analysis, so it works by inducing differentiation. As a part of that process when cells are differentiating and developing, you can actually see what looks to be like an increase in those cells before it actually begins to look better.

And this is another paradigm shift, right? We’re used to seeing all those numbers go down and bottom out. And when that doesn’t do it and it’s AML, we get a little uncertain. So, you have to understand the mechanism of action. What is that drug doing in the system? What do we expect it to do? And stick with it long enough to actually have the opportunity for benefit.

So you’re really changing the dynamics of the disease by giving that treatment, and that’s going to take a little bit of time. Several months of treatment may be required and you want to continue the daily itacitinib. It’s generally well tolerated in the study.

Here’s the data from the phase I/II study of itacitinib; really pretty well tolerated. Some diarrhea and fatigue, but most of these were mild or moderate in severity. Vomiting could be well managed. Other serious related adverse events were rare, but there is this phenomenon called the differentiation syndrome. And
you saw the examples that Dr. Harvey showed and that Dr. Artz showed, but basically if you’ve ever treated somebody for APL, it’s the same kind of thing; they have this flurry of maturing cells that can cause fevers, chills, pulmonary infiltrates, shortness of breath that can be very effectively treated with steroids; if in doubt, give steroids. And it generally passes with time as you moved past that initial differentiation. Really important to keep an eye on that and the trajectory, again, of the disease that can take several weeks to see benefit.

In the studies, permanent withdrawal of the drug was not required, so people worked through it. They didn’t stop the drug unless there was something very severe going on. And you can see the CRs with incomplete hematological recovery was 28% in this group of relapsed patients, high-risk treatment-related, and higher risk patients just by virtue of having relapsed. They received 100 mg a day, and the median time to first or best response was 1.9 to 3.7 months—so way, way, way beyond the 14 and 28 days, right? So you just forget about it and no more. Fourteen and 28 does not apply in this situation. We need to look at it in a different way.

This is just showing that evolution of best response, so it takes time. Also very important to keep in mind, you can see that the depth of response actually improved over time. This is just getting back to some of that safety information. We talked about the differentiation syndrome. Most of these were not of higher grade. They were mostly minor or grade 1/2 as opposed to grade 3/4, but there were some grade 3, which is what’s represented here. Keeping in mind differentiation syndrome, all the things that come with treatment of leukemia,
which are cytopenias; not a surprise. Fatigue, also. And then, there were some cases of increase lipase levels.

Gemtuzumab ozogamicin. How many of you guys used that the first time around, right? So we’re dating ourselves. The problem there is they have dosing that led to some problems with people in terms of infectious complications in particular, and then their endpoints were not met in these trials. And so it got shelved and then got brought back with different dosing parameters and actually has now been approved in three different indications—which I don’t have all on this slide here—but, basically, came back and now was approved very recently—September 1st—with lower recommended dosing.

The other drug that came about and everyone was really excited about this—this was another anti-CD33 drug—dacetuzumab. Really looked exciting and the data looked very exciting. And, unfortunately, they had to withdraw this drug from the market due to patient deaths. And so, this happens in trials where people see deaths and the drug doesn’t get to move forward.

The other drug, vosaroxin, is a first-in-class anticancer quinolone derivative, so a very novel compound. This is something that interplays DNA and inhibits the topo II and basically not a P-gp substrate. So your p-glycoprotein is something that basically allows the drugs to be pumped out of the cells so that you can’t get them in there to affect the DNA. So it’s important when that’s not an issue, a p53-independent activity. And so, this is being looked at in this VALOR trial and translated to prolong survival in relapse/refractory AML, particularly in older patients, so we’ll see how that goes.
Bcl-2, which is a very unique mitochondrial point of activity in AML, venetoclax, which we’re already using in other disease states. This is a highly selective orally bioavailable BH3 mimetic, so basically, that’s that particular pathway. The Bcl-2 proteins are very critical to apoptosis, and Bcl-2 is overexpressed in AML, so it makes that a very attractive target. This was a phase II study looking at 800 mg a day; this is higher than what we use in CLL. Overall response of 19% as a single agent, so showing some activity.

Interestingly, IDH1 and 2 mutations were present in 38% of those patients, and that becomes an interesting though. And toxicity profile pretty manageable.

This is now looking at now that we have these drugs where we can attract these novel targets? It makes sense to start to combine them, right? So you’re coming at things from different angles, so much like adding the FLT3 inhibitor to 7+3. How can we exploit different targets at the same time? This is a phase IB study, so a very early study; venetoclax plus a hypomethylating agent in patients with newly diagnosed AML over the age of 65. And 34 patients in this study, median age of 73, adverse risk in a big number of 41%. And they’re treated with venetoclax 400 or 800 with either decitabine or azacitidine and CR plus a CRi of 71%. So, looking, honestly, how some of these people may have responded to the hypomethylater alone; but, again, an interesting combination.

Where are we are going from here? Well, we’re going to look at all these molecular profiles. We’re going to have to live and breathe all this; this is the way forward. Looking at protein kinase inhibitors, epigenetic modulators, mitochondrial inhibitors, such as the Bcl-2 inhibitors; many other things that
being evaluated. And then how are we going to combine all of these as we move forward? It’s an exciting time; there’s a lot of good work happening. We’re going to see more and more of these things moving forward. And I’m going to turn it over to you.

GABRIELLE All right. Thank you, Sandy; that was an incredible amount of information.

I’m going to go through a couple of case studies in AML to try to put in a little real-life context. Our first case is a 36-year-old gentleman who was diagnosed with AML in July of 2016. He actually presented with a very high white count of 84,000. He was mildly anemic, mildly thrombocytopenic, but he had 30% circulating blasts. He was \textit{NPM1} positive, \textit{FLT3} negative, and \textit{IDH2} positive. His cytogenetics were notable for deletion 16q. He had good cardiac function, and his exam was really unremarkable.

His toxicities included pancytopenia and transfusion dependence, which you would expect from his G-CLAM and consolidation. He went on to get a second consolidate—the pancytopenia in our center is classified ANC of less than 500, at which point they go on Levaquin and posaconazole. They get acyclovir throughout their induction and consolidation.

He also had mucositis and neutropenic fever, which for us, again, less than 500 and a temp greater than 38.3 always get admitted. This poor gentleman was bacteremic with a MDR E. coli, and he was actually septic.

I’m going to take a break from the AML piece of this and just talk about some of the side effects that we deal with. I’m sure you’ve all heard of the
surviving sepsis campaign; there’s a website there that you can look at for a little bit more detail. But we really want to use the good tools that we have. qSOFA is probably by far the best screening tool that we have, and that includes an altered mental status, tachypnea with a respiratory rate of greater than 22, and hypotension with a systolic less than 100. Some people do like to use SIRS, but all it takes is your neutropenic patient to have a fever and they already have met the SIRS criteria.

The other soft indicators are do they look toxic? What does the family think? Usually they have caregivers that are coming in with them and say, “Joe just doesn’t look right,” or “We can’t get him off the couch,” et cetera. What are you going to do? Labs; you want to get blood cultures, two please: one from the line, one peripheral. Get a urine culture and a chest x-ray if you can. Venous lactate is really helpful for following the trajectory. If they’re hypotensive, you want to give them fluid bolus. And when I say fluid bolus, I mean 30 mL per kilo per hour; that’s two liters for a 70 kg individual. The lactate should also be followed just to make sure that they’re responding to what you’re doing.

Antibiotics within 3 hours is the goal set by the surviving sepsis campaign. Ideally, the sooner you get him in—preferably an hour—the better. You want to make sure that you’re reassessing your vitals and fluids on a regular basis. This is the 2006 study from the Critical Care Medicine. It is retrospective, but it’s 2,000 patients that showed a marked survival advantage if antibiotics were given in less than an hour or an hour or less; 80%, which is pretty amazing.
Back to our gentleman. He finally got out of the ICU, got discharged. His marrow showed no evidence of disease. His previously noted NPM1 positivity had gone away, as had his cytogenetic abnormalities. He got admitted for HiDAC and, unfortunately, on day 22 presented with circulating blasts. So he gets cytarabine and decitabine, to which he did not respond. And he was started on intermediate dose of cytarabine with itacitinib started on day 17; he tolerated this actually pretty well. He had quite a bit of nausea, but as you know, we have some great treatments to address this.

He was not eating, which was really problematic for this guy because he’s only 36. But he actually did really well on this therapy. I don’t know exactly where he is in his therapy today, but he did really well. This is a great example of using this particular drug in a relapse/refractory setting.

Our next case is a 72-year-old gentleman who presented to a community hospital. He had progressive fatigue that had been present for quite a while. He had previously been very active—golfer—but had gotten more and more fatigued to the point where he wasn’t able to carry on his usual activities. He hadn’t seen a medical provider for 16 years and was taking no medications.

So when he was first seen in the outside ER, he was febrile to 38.5, he had flu-like symptoms, and profound fatigue. His labs were notable for a creatinine that was slightly elevated at 1.35. His LDH was markedly elevated at 629; upper limit of normal is 180. His albumin was slightly decreased at 3.1, INR was 1.26. He had 161,000 white cells, profoundly anemic, and thrombocytopenic, and had a high amount of circulating blasts. So he was admitted to the hospital.
for IV antibiotics. He got hydroxyurea and fluids while his workup was completed. He really did not want to be in the hospital. Fortunately, we were able to support him on an outpatient basis with regard to his transfusions while we were completing his workup.

His past medical history is actually notable for Hodgkin’s disease; he got ABVD and radiation. And, essentially, after he completed that therapy, that’s when he decided he wasn’t going to have anything to do with medical people. What are we worried about here with a white count of 161,000? Yep, tumor lysis syndrome.

There’s a lot of risk factors we can look at; the tumor type. Burkitt lymphoma is a very high-grade lymphoma, and, obviously, that’s going to be very high risk for tumor lysis, their tumor burden. Elevated LDH; you’ll notice that’s more than two times the upper limit of normal. Elevated white count greater than 25,000, renal function, and a baseline uric acid. So stratification by risk, this gentleman had AML. White count was really very high; he also had a high LDH, so he had a pretty good risk for tumor lysis. Fortunately, we were able to get a lot of these factors corrected by the time he got discharged to the outpatient setting.

In terms of managing tumor lysis syndrome, you don’t want to be in a position where you’re having to follow those items on the left-hand side. You want to be very aggressive in your hydration; you can use sodium bicarb if that’s appropriate. You want to have them starting on allopurinol immediately and, in severe cases, rasburicase; very expensive, but very effective.
Going back to our gentleman; the rest of his workup showed an LV function of 52%, so on the low side, but okay. His marrow showed, not surprisingly, 90% blasts, he was \textit{NPM1} positive and \textit{FLT3} negative. His cytogenetics were notable for deletion 5q and trisomy 8. So, in all likelihood, he had MDS probably for a while that was related to his treatment with ABVD.

I’m just going to take a minute to talk about treatment-related mortalities, treatment mortality index. On the top line here, you can see there is about 12 or 13 factors that help us identify people who are at high risk for dying within the first 28 days with standard of care. You can see on the lower right side there 0% chance of survival. Seventy-two-year-old treatment-related MDS that had progressed to AML.

We’re trying to think out of the box about what we could do for this gentleman. And he was actually enrolled in the CPX-351 trial. He got induction therapy in an outpatient setting, mostly because he refused to be admitted, and he did really well. He had no problems with the infusion itself. He was able to come because his family, his son actually, came up from California and was his primary caregiver, so he was coming back to our center on a 3-to-5 days a week basis.

So, toxicities. Sandy talked a little bit about prolonged cytopenias, and he had a little bit of that; it really wasn’t too bad for him. We’ll talk a little bit about transfusion dependence; most of our AML patients do get transfusion dependent. We use a platelet threshold of less than or equal to 10 or hematocrit of less than or equal to 25. Obviously, those things can be adapted if you have a patient that
has a recent bleeding history or cardiac issues where they just don’t tolerate a lower hematocrit.

The other thing I want to just add to that is that if you have a patient that you think in any way is going to go to transplant, you need to make sure they’re getting irradiated and CMV safe blood products.

Unfortunately for this guy, his day 28 marrow showed persistent disease with 40% blasts. He got re-induced with CPX-351. Again, in the outpatient setting. He tolerated it very well. He did get admitted with a neutropenic fever, transfusion dependence; the usual side effects of treatment. He had count recovery slightly delayed at day 36. His day 38 marrow was normal cellular by morphology, his flow was negative. He did have no abnormal blasts, but he was NPM1 positive. So, he had two cycles of consolidation with CPX-351 that was completed in 2016 and then he was, of course, lost to follow-up because he didn’t want to come back and see us. We’ve probably all had patients like that.

He really did well until June of 2017 when he finally called us and said, “I can’t even get out of bed.” He came in and he had relapsed disease with 42% blasts. But, I’ll tell you, this gentleman that had a risk of treatment-related mortality with a 0% chance at 28 days, he got over a year out of this approach, so it was a pretty phenomenal response.

Our third case is a 62-year-old woman with a 3-year history of thrombocytopenia, which had progressed to pancytopenia. She presented with a white count of 49,000, a little bit anemic, thrombocytopenic; not terribly. She did have 76% circulating blasts. Her chemistries were pretty normal: creatinine 0.8,
LDH 224, slightly elevated, but not terrible. Uric acid was normal at 4.8, bone marrow showed 60% blasts. She had trisomy 8, NPM1 positive, and FLT3 positive. She was extremely anxious, but otherwise, she actually looked pretty good despite her anxiety.

Going back to something Sandy talked about with the European leukemia and that risk stratification, she is intermediate risk with a mutated NPM1 and FLT3 positivity. She got standard 7+3. She did really well with the infusion; no toxicity. She did not have any cerebellar issues. She was discharged on day 6.

At our center, we are fortunate enough to have great outpatient support, and our patients can qualify for early discharge, so they’re not in the hospital for a month waiting for their counts to recover. Essentially, we use age less than 65; they have to be within 15, 20 minutes of the medical center, be willing to come in for three times a week labs and associated transfusions, and a caregiver with a patient.

She started on midostaurin on day 8, and she really did well. She tolerated the drugs and the treatment very well. She did get admitted with a cellulitis, but that resolved with IV antibiotics and she got discharged. Her day 28 marrow showed no evidence of AML. She got consolidation with HiDAC. Again, early discharge, did not have to get readmitted, and got started on the midostaurin again on days 8 through 21; usual toxicities of treatment. This lady actually arrived to our transplant service in October of AMS-unrelated donor transplant in first CR, so this is a good success story.
I’m going to touch upon the Stem Cell Transplant Comorbidity Index. This actually takes into account 17 systems of potential organ dysfunction and gives you a composite of how is this patient going to do in transplant? I will just leave you with the thought that you can look at all of these things—you want to factor them into your decision making—but nothing’s going to take place of a transplant consult because they’re going to look at what are the condition regimens that patient might get? What are the donors? Do they have a match sibling? Do they have an unrelated donor or a Haplo-Cord? There’s a lot of factors that go into this, aside from the comorbidity index.

In summary: lots of tools out there; please use them because it really could help direct your therapy and into better outcomes for your patients. We have a lot of targeted therapies that are now available and they’re a wonderful addition to therapy. They’re very well tolerated in the experiences that we’ve had in our center. And keep the toxicities in mind; plan for your patients to get transfusions; look out for tumor lysis syndrome, since this is a big player and there’s a lot of work out in the community trying to decrease morbidity and mortality associated with sepsis. And then, finally, differentiation syndrome is something to keep an eye out for in certain classes of drugs. All right, everybody got all that committed to memory?

SANDY Any questions; anybody have any questions? There’s somebody; just two of them.

FEMALE Yes. How long after you start treatment with the itacitinib would you expect to look for symptoms of differentiation syndrome?
SANDY The onset can be anywhere from a few weeks to several weeks, so really you want to be really keeping an eye on people as early as 2 weeks out, 10 days to 14 days out and then, up and through—really keeping an eye on people. During that time of response is when you’re going to see it. So, even though the time to response was 1.9 to 3.7 months, you can actually see the differentiation syndrome starting a little ahead of that. So really being astute to those symptoms throughout that period of time because that’s where you’re seeing the differentiation. There was somebody else that had a question over here.

FEMALE —because I understand there might be an algorithm that you were thinking or developing? One of the people I work with are, you know, we’re all groupies for you, but just to differentiate to infection.

SANDY We were just talking about having kind of a roadmap about, how does that look time to onset? What kind of things might you see? It can be a little misleading because we’re in this paradigm of expecting all the numbers to drop and be zero, right? And, instead, what you’re seeing is actually things going up. And when you’re looking at the leukemic blasts—they’re generally of the neutrophil lineage—that myeloid lineage that’s going up and so, you’re worried because it’s going up instead of down or you’re not seeing it go down and then they can develop those secondary symptoms.

So, it can be a little misleading to people and this is why you have to say, “Okay, you know what? I’m using this drug and this is what I’m expecting.” And you can use an analogy to people that are going to ibrutinib for CLL where the
number’s actually going up because of the change in the migration of the cells out of the nodal region into there peripheral blood, so it’s a totally different shift, and it’s based on the mechanism of action of the drug.

If we think about how the drug works, it’s a differentiating agent. Cells are going to mature and develop and grow where normally they’ve been blunted because of the leukemic clone. Then you’re going to see the numbers go up or not go down, which you would normally expect to see in standard therapy. It’s just a totally different way of setting expectations really. Do you have something to add to that, Gabe?

SANDY Over there.

FEMALE (Inaudible)

SANDY Steroids.

FEMALE Antibiotics, too?

SANDY No, they’re just steroids usually.

FEMALE Yeah.

SANDY When you think about what’s differentiating, right? These are the cytokines that come with that differentiation, that development, of those cells are what are producing these symptoms, so, basically, it’s steroids. In some cases, if they have fluid that comes with that, you give diuretics, but it’s the same thing you would do to treat differentiation syndrome in APL.

GABRIELLE And it depends where they are in treatment because there are times if they’re neutropenic and you don’t know exactly what’s causing their fever—
FEMALE  That’s why I was asking because sometimes I understand that there can be like maybe mild dyspnea on presentation and maybe a little bit of hypoxia versus—so, it just seems like a complex—

GABRIELLE  You probably want to do more than one thing at a time and then peel back one at a time your therapy, so once you figure out exactly what’s causing the problem.

SANDY  Yeah. You have to actually do the clinical workup. This is why you need the baseline chest x-ray, or if that doesn’t answer it, get a CT of the chest. But if you’re really worried about differentiation, then steroids are really going to take care of it, yeah.

FEMALE  Thank you.

SANDY  Anybody else? All right, don’t forget to claim your credits and complete your evaluations, please. Thank you for sticking out this long day and have a wonderful night’s sleep or a wonderful time with your nightcap, whichever you choose. And, hopefully, we’ll see you tomorrow for our closing program. Have a good evening; thank you.

[END]